Mathematical modeling of HIV/HTLV co-infection with CTL-mediated immunity

A. M. Elaiw\textsuperscript{1,2,*}, N. H. AlShamrani\textsuperscript{1,3} and A. D. Hobiny\textsuperscript{1}

\textsuperscript{1} Department of Mathematics, Faculty of Science, King Abdulaziz University, P. O. Box 80203, Jeddah 21589, Saudi Arabia
\textsuperscript{2} Department of Mathematics, Faculty of Science, Al-Azhar University, Assiut Branch, Assiut, Egypt
\textsuperscript{3} Department of Mathematics, Faculty of Science, University of Jeddah, P. O. Box 80327, Jeddah 21589, Saudi Arabia

* Correspondence: E-mail: a_m_elaiw@yahoo.com.

Abstract: In the literature, a great number of HIV and HTLV-I mono-infection models has been formulated and analyzed. However, the within-host dynamics of HIV/HTLV-I co-infection has not been modeled. In the present paper we formulate and analyze a new HIV/HTLV-I co-infection model with latency and Cytotoxic T lymphocytes (CTLs) immune response. The model describes the interaction between susceptible CD4\textsuperscript{+}T cells, latently HIV-infected cells, actively HIV-infected cells, latently HTLV-infected cells, Tax-expressing HTLV-infected cells, free HIV particles, HIV-specific CTLs and HTLV-specific CTLs. The HIV can spread by virus-to-cell and cell-to-cell transmissions, while the HTLV-I can only spread via cell-to-cell transmission. The well-posedness of the model is established by showing that the solutions of the model are nonnegative and bounded. We derive the threshold parameters which govern the existence and stability of all equilibria of the model. We prove the global asymptotic stability of all equilibria by utilizing Lyapunov function and Lyapunov-LaSalle asymptotic stability theorem. We have presented numerical simulations to illustrate the effectiveness of our main results. In addition, we have discussed the effect of HTLV-I infection on the HIV-infected patients and vice versa. We have pointed out the influence of CTL immune response on the co-infection dynamics.

Keywords: HIV/HTLV-I co-infection; global stability; CTL-mediated immune response; Lyapunov function

Mathematics Subject Classification: 34D20, 34D23, 37N25, 92B05.
1. Introduction

During the last decades, different dangerous viruses have been recognized which attack the human body and cause many fatal diseases. As an example of these viruses, the human immunodeficiency virus (HIV) which is the causative agent for acquired immunodeficiency syndrome (AIDS). According to the global health observatory (GHO, 2018) data of HIV/AIDS published by WHO [1] that says, globally, about 37.9 million HIV-infected people in 2018, 1.7 million newly HIV-infected and 770,000 HIV-related death in the same year. HIV is a retrovirus that infects the susceptible CD4+T cells which play a central role in immune system defence. During the last decades, mathematical modeling of within-host HIV infection has witnessed a significant development [2]. Nowak and Bangham [3] have introduced the basic HIV infection model which describes the interaction between three compartments, susceptible CD4+T cells (S), actively HIV-infected cells (I) and free HIV particles (V). Latent viral reservoirs remain one of the major hurdles for eradicating the HIV by current antiviral therapy. Latently HIV-infected cells include HIV virions but do not produce them until they become activated. Mathematical modeling of HIV dynamics with latency can help in predicting the effect of antiviral drug efficacy on HIV progression [4]. Rong and Perelson [5] have incorporated the latently infected cells in the basic HIV model presented in [3] as:

\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_1 SV, \\
\dot{L} &= (1 - \beta) \eta_1 SV - (\lambda + \gamma) L, \\
\dot{I} &= \beta \eta_1 SV + \lambda L - aI, \\
\dot{V} &= bI - \varepsilon V,
\end{align*}
\]

(1.1)

where \( S = S(t), L = L(t), I = I(t) \) and \( V = V(t) \) are the concentrations of susceptible CD4+T cells, latently HIV-infected cells, actively HIV-infected cells and free HIV particles at time \( t \), respectively. The susceptible CD4+T cells are produced at specific constant rate \( \rho \). The HIV virions can replicate using virus-to-cell (VTC) transmission. The term \( \eta_1 SV \) refers to the rate at which new infectious appears by VTC contact between free HIV particles and susceptible CD4+T cells. Latently HIV-infected cells are transmitted to be active at rate \( \lambda L \). The free HIV particles are generated at rate \( bI \). The natural death rates of the susceptible CD4+T cells, latently HIV-infected cells, actively HIV-infected cells and free HIV particles are given by \( \alpha S, \gamma L, aI \) and \( \varepsilon V \), respectively. A fraction \( \beta \in (0,1) \) of new HIV-infected cells will be active, and the remaining part \( 1 - \beta \) will be latent. During the last decades, mathematical modeling and analysis of HIV mono-infection with both latently and actively HIV-infected cells have witnessed a significant development [6–12].

Model (1.1) assumed that the HIV can only spread by VTC transmission. However, several works have reported that there is another mode of transmission called cell-to-cell (CTC) where the HIV can be transmitted directly from an infected cell to a healthy CD4+T cell through the formation of virological synapses [13]. Sourisseau et al. [14] have shown that CTC transmission plays an efficient role in the HIV replication. Sigal et al. [15] have demonstrated the importance of CTC transmission in the HIV infection process during the antiviral treatment. Iwami et al. [13] have shown that about 60% of HIV infections are due to CTC transmission. In addition, CTC transmission can increase the HIV fitness by 3.9 times and decrease the production time of HIV particles by 0.9 times [16]. HIV dynamics model
with latency and both VTC and CTC transmissions is given by \[17, 18\]:

\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_1 SV - \eta_2 SI, \\
\dot{L} &= (1 - \beta)(\eta_1 SV + \eta_2 SI) - (\lambda + \gamma)L, \\
\dot{I} &= \beta(\eta_1 SV + \eta_2 SI) + \lambda L - aI, \\
\dot{V} &= bI - \varepsilon V,
\end{align*}
\]

(1.2)

where, the term $\eta_2 SI$ refers to the rate at which new infectious appears by CTC contact between HIV-infected cells and susceptible CD4$^+$T cells.

Another example of the dangerous human viruses is called Human T-lymphotropic virus type I (HTLV-I) which can lead to two diseases, adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The discovery of the first human retrovirus HTLV-I is back to 1980, and after 3 years the HIV was determined \[19\]. HTLV-I is global epidemic that infects about 10-25 million persons \[20\]. The infection is endemic in the Caribbean, southern Japan, the Middle East, South America, parts of Africa, Melanesia and Papua New Guinea \[21\]. HTLV-I is a provirus that targets the susceptible CD4$^+$T cells. HTLV-I can spread to susceptible CD4$^+$T cells from CTC through the virological synapse. HTLV-infected cells can be divided into two kinds based on the presence of Tax inside the cell or not: (i) Tax$^-$, or latently HTLV-infected cells are resting CD4$^+$T cells that contain a provirus and do not express Tax, and (ii) Tax$^+$, or actively HTLV-infected cells are activated provirus-carrying CD4$^+$T cells that do express Tax \[22\]. During the primary infection stage of HTLV-I, the proviral load can reach high level, approximately 30-50\% \[23\]. Unlike in the case of HIV infection, however, only a small percentage of infected individuals develop the disease and 2-5\% percent of HTLV-I carriers develop symptoms of ATL and another 0.25-3\% develop HAM/TSP \[24\]. Stilianakis and Seydel \[25\] have formulated an HTLV-I model to describe the interaction of susceptible CD4$^+$T cells, latently HTLV-infected cells, Tax-expressing HTLV-infected cells (actively HTLV-infected cells) and leukemia cells (ATL cells) as:

\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_3 SY, \\
\dot{E} &= \eta_3 SY - (\psi + \omega)E, \\
\dot{Y} &= \psi E - (\vartheta + \delta)Y, \\
\dot{Z} &= \vartheta Y + \ell Z \left(1 - \frac{Z}{Z_{\text{max}}} \right) - \theta Z,
\end{align*}
\]

(1.3)

where $S = S(t)$, $E = E(t)$, $Y = Y(t)$ and $Z = Z(t)$ are the concentrations of susceptible CD4$^+$T cells, latently HTLV-infected cells, Tax-expressing HTLV-infected cells and ATL cells, at time $t$, respectively. In contrast of HIV, the transmission of HTLV-I can be only from CTC that is the HTLV virions can only survive inside the host CD4$^+$T cells and cannot be detectable in the plasma. The rate at which new infectious appears by CTC contact between Tax-expressing HTLV-infected cells and susceptible CD4$^+$T cells is assumed to be $\eta_3 SY$. The natural death rate of the latently HTLV-infected cells, Tax-expressing HTLV-infected cells and ATL cells are represented by $\omega E$, $\delta Y$ and $\theta Z$, respectively. The term $\psi E$ accounts for the rate of latently HTLV-infected cells that become Tax-expressing HTLV-infected cells. $\vartheta Y$ is the transmission rate at which Tax-expressing HTLV-infected cells convert to ATL cells. The logistic term $\ell Z \left(1 - \frac{Z}{Z_{\text{max}}} \right)$ denotes the proliferation rate of the ATL cells, where $Z_{\text{max}}$ is the maximal concentration that ATL cells can grow. The parameter $\ell$ is the maximum proliferation rate constant of ATL cells. Many researchers have been concerned to study mathematical modeling and analysis of HTLV-I mono-infection in several works \[26–28\].
Cytotoxic T lymphocytes (CTLs) are recognized as the significant component of the human immune response against viral infections. CTLs inhibit viral replication and kill the cells which are infected by viruses. In fact, CTLs are necessary and universal to control HIV infection [29]. During the recent years, great efforts have been made to formulate and analyze the within-host HIV mono-infection models under the influence of CTL immune response (see e.g. [2, 3]). In [30], latently HIV-infected cells have been included in the HIV dynamics models with CTL immune response. In case of HTLV-I infection, it has been reported in [31] that the CTLs play an effective role in controlling such infection. CTLs can recognize and kill the Tax-expressing HTLV-infected cells, moreover, they can reduce the proviral load. In the literature, several mathematical models have been proposed to describe the dynamics of HTLV-I under the effect of CTL immune response (see e.g. [21, 32–36]). In [20, 37, 38], HTLV-I dynamics models have been presented by incorporating latently HTLV-infected cells and CTL immune response.

Simultaneous infection by HIV and HTLV-I and the etiology of their pathogenic and disease outcomes have become a global health matter over the past 10 years [39]. It is commonly that HIV/HTLV-I co-infection can be endemic in areas where individuals experience high risk attitudes; such as unprotected sexual contact and unsafe injection practices; that cause transmission of contaminated body fluids between individuals. This shed a light on the importance of studying HIV/HTLV-I co-infection [40]. Although CD4+ T cells are the major targets of both HIV and HTLV-I, however, these viruses present a different biological behavior that causes diverse impacts on host immunity and ultimately lead to numerous clinical diseases [41]. It has been reported that the HTLV-I co-infection rate among HIV infected patients as increase as 100 to 500 times in comparison with the general population [42]. In seroepidemiologic studies, it has been recorded that HIV-infected patients are more exposure to be co-infected with HTLV-I, and vice versa compared to the general population [43]. HIV/HTLV-I co-infection is usually found in individuals of specific ethnic or who belonged to geographic origins where these viruses are simultaneously endemic [44]. As an example, the co-infection rates in individuals living in Bahia have reached 16% of HIV-infected patients [45]. The prevalence of dual infection with HIV and HTLV-I has become more widely in several geographical regions throughout the world such as South America, Europe, the Caribbean, Bahia (Brazil), Mozambique (Africa), and Japan [39, 43, 45–47]. HIV and HTLV-I dual infection appears to have an overlap on the course of associated clinical outcomes with both viruses [43]. Several reports have concluded that HIV/HTLV-I co-infected patients were found to have an increase of CD4+ T cells count in comparison with HIV mono-infected patients, although there is no evident to result in a better immune response [41, 48]. Indeed, simultaneous infected patients by both viruses with CD4+ T counts greater than 200 cells/mm³ are more exposure to have other opportunistic infections as compared with HIV mono-infected patients who have similar CD4+ T counts [48]. Studies have reported that higher mortality and shortened survival rates were accompany with co-infected individuals more than mono-infected individuals [46]. Considering the natural history of HIV, many researchers have noted that co-infection with HIV and HTLV-I can accelerate the clinical progression to AIDS. On the other hand, HIV can adjust HTLV-I expression in co-infected individuals which leads them to a higher risk of developing HTLV-I related diseases such as ATL and TSP/HAM [42, 43, 46].

Great efforts have been made to develop and analyze mathematical models of HIV and HTLV-I mono-infections, however, modeling of HIV/HTLV-I co-infection has not been studied. In fact, such co-infection modeling and its analysis will be needed to help clinicians on estimating the appropriate
time to initiate treatment in co-infected patients. Therefore, the aim of the present paper is to formulate a new HIV/HTLV-I co-infection model. We show that the model is well-posed by establishing that the solutions of the model are nonnegative and bounded. We derive a set of threshold parameters which govern the existence and stability of the equilibria of the model. Global stability of all equilibria is proven by constructing suitable Lyapunov functions and utilizing Lyapunov-LaSalle asymptotic stability theorem. We conduct some numerical simulations to illustrate the theoretical results.

The results of this work, such as co-infection model and its analysis will help clinicians estimate the appropriate time for patients with co-infection to begin treatment. On the other hand, this study, from a certain point of view, illustrate the complexity of this co-infection model and the model is helpful to clinic treatment. It is worth mentioning, if we look at research perspectives, that appropriate developments of the model presented in this paper can be focused on the within host modeling of the competition between COVID19 virus and the immune system by a complex dynamics described in [49]. This dynamics which occurs, in human lungs, once the virus, after contagion, has gone over the biological barriers which protect each individuals, see [47].

2. Model formulation

We set up an ordinary differential equation model that describes the change of concentrations of eight compartments with respect to time $t$: susceptible CD4+$^+$T cells $S(t)$, latently HIV-infected cells $L(t)$, actively HIV-infected cells $I(t)$, latently HTLV-infected cells $E(t)$, Tax-expressing HTLV-infected cells $Y(t)$, free HIV particles $V(t)$, HIV-specific CTLs $C^I(t)$ and HTLV-specific CTLs $C^Y(t)$. The dynamics of HIV/HTLV-I co-infection is schematically shown in the transfer diagram given in Figure 1. Our proposed model is given by the following form:
\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_1 SV - \eta_2 SI - \eta_3 SY, \\
\dot{L} &= (1 - \beta) (\eta_1 SV + \eta_2 SI) - (\lambda + \gamma) L, \\
\dot{I} &= \beta (\eta_1 SV + \eta_2 SI) + \lambda L - aI - \mu_1 CI, \\
\dot{E} &= \varphi I S Y - (\psi + \omega) E, \\
\dot{Y} &= \psi E - \delta Y - \mu_2 C^Y Y, \\
\dot{V} &= bI - \epsilon V, \\
\dot{C}_1 &= \sigma_1 C^I I - \pi_1 C^I, \\
\dot{C}^Y &= \sigma_2 C^Y Y - \pi_2 C^Y,
\end{align*}
\] (2.1)
where \((S, L, I, E, Y, V, C^I, C^Y) = (S(t), L(t), I(t), E(t), Y(t), V(t), C^I(t), C^Y(t))\). The term \(\mu_1 C^I I\) is the killing rate of actively HIV-infected cells due to their specific immunity. The term \(\mu_2 C^Y Y\) is the killing rate of Tax-expressing HTLV-infected cells due to their specific immunity. The proliferation and death rates for both effective HIV-specific CTLs and HTLV-specific CTLs are given by \(\sigma_1 C^I I, \sigma_2 C^Y Y, \pi_1 C^I\) and \(\pi_2 C^Y\), respectively. All remaining parameters have the same biological meaning as explained in the previous section. All parameters and their definitions are summarized in Table 1.

### Table 1. Parameter description.

| Parameter | Description |
|-----------|-------------|
| \(\rho\) | Recruitment rate for the susceptible CD4\(^{+}\)T cells |
| \(\alpha\) | Natural mortality rate constant for the susceptible CD4\(^{+}\)T cells |
| \(\eta_1\) | Virus-cell incidence rate constant between free HIV particles and susceptible CD4\(^{+}\)T cells |
| \(\eta_2\) | Cell-cell incidence rate constant between HIV-infected cells and susceptible CD4\(^{+}\)T cells |
| \(\eta_3\) | Cell-cell incidence rate constant between Tax-expressing HTLV-infected cells and susceptible CD4\(^{+}\)T cells |
| \(\beta \in (0, 1)\) | Fraction coefficient accounts for the probability of new HIV-infected cells could be active, and the remaining part \(1 - \beta\) will be latent |
| \(\gamma\) | Death rate constant of HIV-infected cells |
| \(a\) | Death rate constant of actively HIV-infected cells |
| \(\mu_1\) | Killing rate constant of actively HIV-infected cells due to HIV-specific CTLs |
| \(\mu_2\) | Killing rate constant of Tax-expressing HTLV-infected cells due to HTLV-specific CTLs |
| \(\varphi \in (0, 1)\) | Probability of new HTLV infections could be enter a latent period |
| \(\lambda\) | Transmission rate constant of latent HIV-infected cells that become actively HIV-infected cells |
| \(\psi\) | Transmission rate constant of latently HTLV-infected cells that become Tax-expressing HTLV-infected cells |
| \(\omega\) | Death rate constant of latently HTLV-infected cells |
| \(\delta\) | Death rate constant of Tax-expressing HTLV-infected cells |
| \(b\) | Generation rate constant of new HIV particles |
| \(\epsilon\) | Death rate constant of free HIV particles |
| \(\sigma_1\) | Proliferation rate constant of HIV-specific CTLs |
| \(\sigma_2\) | Proliferation rate constant of HTLV-specific CTLs |
| \(\pi_1\) | Decay rate constant of HIV-specific CTLs |
| \(\pi_2\) | Decay rate constant of HTLV-specific CTLs |

### 3. Preliminaries

Let \(\Omega_j > 0, j = 1, \ldots, 5\) and define

\[
\Theta = \{(S, L, I, E, Y, V, C^I, C^Y) \in \mathbb{R}_{\geq 0}^8 : 0 \leq S(t), L(t), I(t) \leq \Omega_1, \}
\]
\[ 0 \leq E(t), Y(t) \leq \Omega_2, \quad 0 \leq V(t) \leq \Omega_3, \quad 0 \leq C(t) \leq \Omega_4, \quad 0 \leq C^V(t) \leq \Omega_5 \].

**Proposition 1.** The compact set \( \Theta \) is positively invariant for system (2.1).

*Proof.* We have

\[
\begin{align*}
\dot{S} \big|_{S=0} &= \rho > 0, \\
\dot{L} \big|_{L=0} &= (1 - \beta) (\eta_1 SV + \eta_2 SI) \geq 0 \text{ for all } S, V, I \geq 0, \\
\dot{I} \big|_{I=0} &= \beta \eta_1 SV + \lambda L \geq 0 \text{ for all } S, V, L \geq 0, \\
\dot{E} \big|_{E=0} &= \varphi \eta_3 SY \text{ for all } S, Y \geq 0, \\
\dot{Y} \big|_{Y=0} &= \psi E \geq 0 \text{ for all } E \geq 0, \\
\dot{V} \big|_{V=0} &= bI \geq 0 \text{ for all } I \geq 0, \\
C^I \big|_{C^I=0} &= 0, \\
C^V \big|_{C^V=0} &= 0.
\end{align*}
\]

This ensures that, \( (S(t), L(t), I(t), E(t), Y(t), V(t), C^I(t), C^V(t)) \in \mathbb{R}^8_{\geq 0} \) for all \( t \geq 0 \) when \( (S(0), L(0), I(0), E(0), Y(0), V(0), C^I(0), C^V(0)) \in \mathbb{R}^8_{\geq 0} \). To show the boundedness of all state variables, we let

\[ \Psi = S + L + I + \frac{1}{\varphi} (E + Y) + \frac{\alpha \mu_1}{\sigma_1} C^I + \frac{\mu_2}{\varphi \sigma_2} C^V. \]

Then

\begin{align*}
\Psi &= \rho - \alpha S - \gamma L - \frac{\alpha}{2} - \frac{\omega}{\varphi} E - \delta Y - \frac{\alpha \varphi}{\sigma_1} C^I - \frac{\mu_2}{\varphi \sigma_2} C^V \\
&\leq \rho - \phi \left[ S + L + I + \frac{1}{\varphi} (E + Y) + \frac{\alpha}{2} V + \frac{\alpha \mu_1}{\sigma_1} C^I + \frac{\mu_2}{\varphi \sigma_2} C^V \right] = \rho - \phi \Psi,
\end{align*}

where \( \phi = \min\{\alpha, \gamma, \varphi, \omega, \delta, \varphi, \mu_1, \mu_2\} \). Hence, \( 0 \leq \Psi(t) \leq \Omega_1 \) if \( \Psi(0) \leq \Omega_1 \) for \( t \geq 0 \), where \( \Omega_1 = \frac{\rho}{\phi} \).

Since \( S, L, I, E, Y, V, C^I, \) and \( C^V \) are all nonnegative then \( 0 \leq S(t), L(t), I(t) \leq \Omega_1, 0 \leq E(t), Y(t) \leq \Omega_2, 0 \leq V(t) \leq \Omega_3, 0 \leq C^I(t) \leq \Omega_4, 0 \leq C^V(t) \leq \Omega_5 \) if \( S(0) + L(0) + I(0) + \frac{1}{\varphi} (E(0) + Y(0)) + \frac{\mu_2}{\varphi \sigma_2} V(0) + \frac{\alpha \mu_1}{\sigma_1} C^I(0) + \frac{\mu_2}{\varphi \sigma_2} C^V(0) \leq \Omega_1 \), where \( \Omega_2 = \varphi \Omega_1, \Omega_3 = \frac{2b \Omega_1}{\alpha}, \Omega_4 = \frac{\sigma_1 \Omega_1}{\mu_1} \) and \( \Omega_5 = \frac{\varphi \sigma_2 \Omega_1}{\mu_2} \). \( \square \)

4. Equilibria

In this section, we derive eight threshold parameters which guarantee the existence of the equilibria of the model. Let \( (S, L, I, E, Y, V, C^I, C^V) \) be any equilibrium of system (2.1) satisfying the following equations:

\begin{align*}
0 &= \rho - \alpha S - \eta_1 SV - \eta_2 SI - \eta_3 SY, \\
0 &= (1 - \beta) (\eta_1 SV + \eta_2 SI) - (\lambda + \gamma) L, \\
0 &= \beta (\eta_1 SV + \eta_2 SI) + \lambda L - a I - \mu_1 C^I, \\
0 &= \varphi \eta_3 SY - (\psi + \omega) E, \\
0 &= \psi E - \delta Y - \mu_2 C^V Y, \\
0 &= b I - \varepsilon V, \\
0 &= (\sigma_1 I - \pi_1) C^I, \\
0 &= (\sigma_2 Y - \pi_2) C^V.
\end{align*}

The straightforward calculation finds that system (2.1) admits eight equilibria.
(i) Infection-free equilibrium, $D_0 = (S_0, 0, 0, 0, 0, 0, 0, 0)$, where $S_0 = \rho / \alpha$. This case describes the situation of healthy state where both HIV and HTLV are absent.

(ii) Chronic HIV mono-infection equilibrium with inactive immune response, $D_1 = (S_1, L_1, I_1, 0, 0, V_1, 0, 0)$, where

$$S_1 = \frac{ae(\gamma + \lambda)}{(\beta\gamma + \lambda)(\eta_1 b + \eta_2 \varepsilon)}, \quad L_1 = \frac{ae\alpha(1 - \beta)}{(\beta\gamma + \lambda)(\eta_1 b + \eta_2 \varepsilon)} \left[ \frac{S_0(\beta\gamma + \lambda)(\eta_1 b + \eta_2 \varepsilon)}{ae(\gamma + \lambda)} - 1 \right], \quad I_1 = \frac{e\alpha}{\eta_1 b + \eta_2 \varepsilon} \left[ \frac{S_0(\beta\gamma + \lambda)(\eta_1 b + \eta_2 \varepsilon)}{ae(\gamma + \lambda)} - 1 \right],$$

$$V_1 = \frac{ab}{\eta_1 b + \eta_2 \varepsilon} \left[ \frac{S_0(\beta\gamma + \lambda)(\eta_1 b + \eta_2 \varepsilon)}{ae(\gamma + \lambda)} - 1 \right].$$

Therefore, $D_1$ exists when

$$\frac{S_0(\beta\gamma + \lambda)(\eta_1 b + \eta_2 \varepsilon)}{ae(\gamma + \lambda)} > 1.$$ 

At the equilibrium $D_1$ the chronic HIV mono-infection persists while the immune response is unstimulated. The basic HIV mono-infection reproductive ratio for system (2.1) is defined as:

$$\mathcal{R}_1 = \frac{S_0(\beta\gamma + \lambda)(\eta_1 b + \eta_2 \varepsilon)}{ae(\gamma + \lambda)} = \mathcal{R}_{11} + \mathcal{R}_{12},$$

where

$$\mathcal{R}_{11} = \frac{S_0\eta_1 b (\beta\gamma + \lambda)}{ae(\gamma + \lambda)}, \quad \mathcal{R}_{12} = \frac{S_0\eta_2 (\beta\gamma + \lambda)}{a(\gamma + \lambda)}.$$ 

The parameter $\mathcal{R}_1$ determines whether or not a chronic HIV infection can be established. In fact, $\mathcal{R}_{11}$ measures the average number of secondary HIV infected generation caused by an existing free HIV particles, while $\mathcal{R}_{12}$ measures the average number of secondary HIV infected generation caused by an HIV-infected cell. Therefore, $\mathcal{R}_{11}$ and $\mathcal{R}_{12}$ are the basic HIV mono-infection reproductive ratio corresponding to VTC and CTC infections, respectively. In terms of $\mathcal{R}_1$, we can write

$$S_1 = \frac{S_0}{\mathcal{R}_1}, \quad L_1 = \frac{ae\alpha(1 - \beta)}{(\beta\gamma + \lambda)(\eta_1 b + \eta_2 \varepsilon)} (\mathcal{R}_1 - 1), \quad I_1 = \frac{e\alpha}{\eta_1 b + \eta_2 \varepsilon} (\mathcal{R}_1 - 1), \quad V_1 = \frac{ab}{\eta_1 b + \eta_2 \varepsilon} (\mathcal{R}_1 - 1).$$

(iii) Chronic HTLV mono-infection equilibrium with inactive immune response, $D_2 = (S_2, 0, 0, E_2, Y_2, 0, 0, 0)$, where

$$S_2 = \frac{\delta (\psi + \omega)}{\varphi \eta_3 \psi}, \quad E_2 = \frac{\alpha \delta}{\eta_3 \psi} \left[ \frac{\varphi \eta_3 \psi S_0}{\delta (\psi + \omega)} - 1 \right], \quad Y_2 = \frac{\alpha}{\eta_3} \left[ \frac{\varphi \eta_3 \psi S_0}{\delta (\psi + \omega)} - 1 \right].$$

Therefore, $D_2$ exists when

$$\frac{\varphi \eta_3 \psi S_0}{\delta (\psi + \omega)} > 1.$$ 

At the equilibrium $D_2$ the chronic HTLV mono-infection persists while the immune response is unstimulated. The basic HTLV mono-infection reproductive ratio for system (2.1) is defined as:

$$\mathcal{R}_2 = \frac{\varphi \eta_3 \psi S_0}{\delta (\psi + \omega)}.$$ 

The parameter $\mathcal{R}_2$ decides whether or not a chronic HTLV infection can be established. In terms of $\mathcal{R}_2$, we can write

$$S_2 = \frac{S_0}{\mathcal{R}_2}, \quad E_2 = \frac{\alpha \delta}{\eta_3 \psi} (\mathcal{R}_2 - 1), \quad Y_2 = \frac{\alpha}{\eta_3} (\mathcal{R}_2 - 1).$$

AIMS Mathematics

Volume 6, Issue 2, 1634–1676.
Remark 1. We note that both $\mathcal{R}_1$ and $\mathcal{R}_2$ does not depend of parameters $\sigma_i$, $\pi_i$ and $\mu_i$, $i = 1, 2$. Therefore, without treatment CTLs will not able to clear HIV or HTLV-I from the body.

(iv) Chronic HIV mono-infection equilibrium with only active HIV-specific CTL, $D_3 = (S_3, L_3, I_3, 0, 0, V_3, C^I_3, 0)$, where

$$S_3 = \frac{\varepsilon \rho_1 (1 - \beta) (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1}{\pi_1 (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1}, \quad L_3 = \frac{\rho \pi_1 (1 - \beta) (\eta_1 b + \eta_2 \varepsilon)}{(\gamma + \lambda) \pi_1 (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1}, \quad I_3 = \frac{\pi_1}{\sigma_1},$$

$$V_3 = \frac{b \varepsilon \sigma_1}{\pi_1 (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1}, \quad C^I_3 = \frac{a}{\mu_1} \left[ \frac{\sigma_1 \rho (\beta \gamma + \lambda) (\eta_1 b + \eta_2 \varepsilon)}{a (\gamma + \lambda) \pi_1 (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1} - 1 \right].$$

We note that $D_3$ exists when $\frac{\sigma_1 \rho (\beta \gamma + \lambda) (\eta_1 b + \eta_2 \varepsilon)}{a (\gamma + \lambda) \pi_1 (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1} > 1$. The HIV-specific CTL-mediated immunity reproductive ratio in case of HIV mono-infection is stated as:

$$\mathcal{R}_3 = \frac{\sigma_1 \rho (\beta \gamma + \lambda) (\eta_1 b + \eta_2 \varepsilon)}{a (\gamma + \lambda) \pi_1 (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1}.$$ 

Thus, $C^I_3 = \frac{a}{\mu_1} (\mathcal{R}_3 - 1)$. The parameter $\mathcal{R}_3$ determines whether or not the HIV-specific CTL-mediated immune response is stimulated in the absent of HTLV infection.

(v) Chronic HTLV mono-infection equilibrium with only active HTLV-specific CTL, $D_4 = (S_4, 0, 0, E_4, Y_4, 0, 0, C^I_4)$, where

$$S_4 = \frac{\sigma_2 \rho}{\pi_2 \eta_3 + \alpha \sigma_2}, \quad Y_4 = \frac{\pi_2}{\sigma_2}, \quad E_4 = \frac{\pi_2 \eta_3 \rho \varphi}{(\psi + \omega) (\pi_2 \eta_3 + \alpha \sigma_2)}, \quad C^I_4 = \frac{\delta}{\mu_2} \left[ \frac{\sigma_2 \rho \varphi \eta_3 \psi}{\delta (\psi + \omega) (\pi_2 \eta_3 + \alpha \sigma_2)} - 1 \right].$$

We note that $D_4$ exists when $\frac{\sigma_2 \rho \varphi \eta_3 \psi}{\delta (\psi + \omega) (\pi_2 \eta_3 + \alpha \sigma_2)} > 1$. The HTLV-specific CTL-mediated immunity reproductive ratio in case of HTLV mono-infection is stated as:

$$\mathcal{R}_4 = \frac{\sigma_2 \rho \varphi \eta_3 \psi}{\delta (\psi + \omega) (\pi_2 \eta_3 + \alpha \sigma_2)}.$$ 

Thus, $C^I_4 = \frac{\delta}{\mu_2} (\mathcal{R}_4 - 1)$. The parameter $\mathcal{R}_4$ determines whether or not the HTLV-specific CTL-mediated immune response is stimulated in the absent of HIV infection.

(vi) Chronic HIV/HTLV co-infection equilibrium with only active HIV-specific CTL, $D_5 = (S_5, L_5, I_5, E_5, Y_5, V_5, C^I_5, 0)$, where

$$S_5 = \frac{\delta (\psi + \omega)}{\varphi \eta_3 \psi} = S_2, \quad I_5 = \frac{\pi_1}{\sigma_1} = I_3,$$

$$V_5 = \frac{b \pi_1}{\varepsilon \sigma_1} = V_3, \quad L_5 = \frac{\delta \pi_1 (1 - \beta) (\psi + \omega) (\eta_1 b + \eta_2 \varepsilon)}{\varepsilon \eta_3 \sigma_1 \varphi \psi (\gamma + \lambda)},$$

$$E_5 = \frac{\delta \pi_1 (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1}{\varepsilon \eta_3 \sigma_1 \psi} \left[ \frac{\rho \varphi \varepsilon \eta_3 \sigma_1 \psi}{\delta (\psi + \omega) [\pi_1 (\eta_1 b + \eta_2 \varepsilon) + \alpha \varepsilon \sigma_1]} - 1 \right].$$
Thus, we note that \( \text{AIMS Mathematics} \) could be co-infected with HIV.

The HTLV infection reproductive ratio in the presence of HIV infection is stated as:

\[
\mathcal{R}_5 = \frac{\rho \varphi \eta \sigma_1 \psi}{\delta (\psi + \omega)} \left( \frac{\rho \varphi \eta \sigma_1 \psi}{\delta (\psi + \omega)} \right).
\]

Thus, \( E_5 = \frac{\rho \varphi \eta \sigma_1 \psi}{\delta (\psi + \omega)} \left( \frac{\rho \varphi \eta \sigma_1 \psi}{\delta (\psi + \omega)} \right) \) and \( Y_5 = \frac{\rho \varphi \eta \sigma_1 \psi}{\delta (\psi + \omega)} \left( \frac{\rho \varphi \eta \sigma_1 \psi}{\delta (\psi + \omega)} \right) \). The parameter \( \mathcal{R}_5 \) determines whether or not HIV-infected patients could be co-infected with HTLV.

(vii) Chronic HIV/HTLV co-infection equilibrium with only active HTLV-specific CTL, \( D_0 = (S_6, L_6, I_6, E_6, Y_6, V_6, 0, C_6^V) \), where

\[
S_6 = \frac{ae (\gamma + \lambda)}{\beta (\gamma + \lambda)} = S_1, \quad L_6 = \frac{ae (1 - \beta) (\pi_2 \eta_3 + \alpha \sigma_2)}{\beta (\gamma + \lambda)} \left( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \right), \quad Y_6 = \frac{\pi_2}{\sigma_2} Y_4, \quad V_6 = \frac{b (\pi_2 \eta_3 + \alpha \sigma_2)}{\beta (\gamma + \lambda)} \left( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \right) - 1, \quad C_6^V = \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \left( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \right) - 1.
\]

We note that \( D_6 \) exists when \( \mathcal{R}_2 / \mathcal{R}_1 > 1 \) and \( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \left( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \right) > 1 \). The HIV infection reproductive ratio in the presence of HTLV infection is stated as:

\[
\mathcal{R}_6 = \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \left( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \right).
\]

Thus, \( L_6 = \frac{ae (1 - \beta) (\pi_2 \eta_3 + \alpha \sigma_2)}{\beta (\gamma + \lambda)} \left( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \right), \quad I_6 = \frac{e (\pi_2 \eta_3 + \alpha \sigma_2)}{\beta (\gamma + \lambda)} \left( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \right) - 1, \quad V_6 = \frac{b (\pi_2 \eta_3 + \alpha \sigma_2)}{\beta (\gamma + \lambda)} \left( \frac{\rho \sigma_2 (\beta \gamma + \lambda)}{ae (\gamma + \lambda)} \right) - 1 \). The parameter \( \mathcal{R}_6 \) determines whether or not HTLV-infected patients could be co-infected with HIV.

(viii) Chronic HIV/HTLV co-infection equilibrium with active HIV-specific CTL and HTLV-specific CTL, \( D_7 = (S_7, L_7, I_7, E_7, Y_7, V_7, C_7, C_7^V) \), where

\[
S_7 = \frac{e \sigma_1 \sigma_2 \rho}{\pi_1 \sigma_2 (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \sigma_1 \rho + \alpha \sigma_1 \sigma_2}, \quad L_7 = \frac{\pi_1 \sigma_2 (1 - \beta) (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \sigma_1 \rho}{(\gamma + \lambda)} \left( \frac{\pi_1 \sigma_2 (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \sigma_1 \rho + \alpha \sigma_1 \sigma_2}{(\gamma + \lambda)} \right), \quad E_7 = \frac{e}{\gamma + \lambda} \left( \frac{\pi_1 \sigma_2 (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \sigma_1 \rho + \alpha \sigma_1 \sigma_2}{(\gamma + \lambda)} \right), \quad I_7 = \frac{I_1}{\sigma_1} = I_3 = I_5, \quad Y_7 = \frac{\pi_2}{\sigma_2} = Y_4 = Y_6, \quad V_7 = \frac{b \pi_1}{\sigma_1} = V_3 = V_5, \quad C_7^V = \frac{\alpha \sigma_1 \rho (\beta \gamma + \lambda) (\eta_1 b + \eta_2 e)}{\mu_1 \left( \frac{\sigma_1 \rho (\beta \gamma + \lambda) (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \sigma_1 \rho + \alpha \sigma_1 \sigma_2}{(\gamma + \lambda)} \right)}.
\]
It is obvious that $D_7$ exists when
\[
\sigma_1 \sigma_2 \rho (\beta \gamma + \lambda) (\eta_1 b + \eta_2 e) > 1
\]
and
\[
\frac{\varphi \eta_3 \varepsilon \sigma_1 \sigma_2 \rho \psi}{\delta (\psi + \omega) \left[ \pi_1 \sigma_2 (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \varepsilon \sigma_1 + \alpha \varepsilon \sigma_1 \sigma_2 \right]} > 1.
\]
Now we define
\[
\mathcal{K}_7 = \frac{\sigma_1 \sigma_2 \rho (\beta \gamma + \lambda) (\eta_1 b + \eta_2 e) \varphi \eta_3 \varepsilon \sigma_1 \sigma_2 \rho \psi}{a (\gamma + \lambda) \left[ \pi_1 \sigma_2 (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \varepsilon \sigma_1 + \alpha \varepsilon \sigma_1 \sigma_2 \right]},
\]
\[
\mathcal{R}_8 = \frac{\varphi \eta_3 \varepsilon \sigma_1 \sigma_2 \rho \psi}{\delta (\psi + \omega) \left[ \pi_1 \sigma_2 (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \varepsilon \sigma_1 + \alpha \varepsilon \sigma_1 \sigma_2 \right]}.
\]
Clearly, $D_7$ exists if $\mathcal{K}_7 > 1$ and $\mathcal{R}_8 > 1$ and we can write $C_7^g = \frac{a}{\mu_1} (\mathcal{K}_7 - 1)$ and $C_7^v = \frac{\delta}{\mu_2} (\mathcal{R}_8 - 1)$.

The parameter $\mathcal{K}_7$ refers to the competed HIV-specific CTL-mediated immunity reproductive ratio in case of HIV/HTLV co-infection. On the other hand, the parameter $\mathcal{R}_8$ refers to the competed HTLV-specific CTL-mediated immunity reproductive ratio case of HIV/HTLV co-infection.

The eight threshold parameters are given as follows:
\[
\begin{align*}
\mathcal{R}_1 &= \frac{S_0 (\beta \gamma + \lambda) (\eta_1 b + \eta_2 e)}{a \varepsilon (\gamma + \lambda)}, & \mathcal{R}_2 &= \frac{\varphi \eta_3 \psi S_0}{\delta (\psi + \omega)}, \\
\mathcal{R}_3 &= \frac{\sigma_1 \rho \varphi (\beta \gamma + \lambda) (\eta_1 b + \eta_2 e)}{a (\gamma + \lambda) \left[ \pi_1 (\eta_1 b + \eta_2 e) + \alpha \varepsilon \sigma_1 \right]}, & \mathcal{R}_4 &= \frac{\varphi \eta \psi \eta_3 \sigma_1 \rho \psi}{\delta (\psi + \omega) (\pi_2 (\pi_3 + \alpha \sigma_2))}, \\
\mathcal{R}_5 &= \frac{\rho \varphi \eta \eta_3 \sigma_1 \rho \psi}{\delta (\psi + \omega) \left[ \pi_1 (\eta_1 b + \eta_2 e) + \alpha \varepsilon \sigma_1 \right]}, & \mathcal{R}_6 &= \frac{\rho \sigma_2 \varphi (\beta \gamma + \lambda) (\eta_1 b + \eta_2 e)}{a \varepsilon (\gamma + \lambda) (\pi_2 \eta_3 + \alpha \sigma_2)}, \\
\mathcal{R}_7 &= \frac{\sigma_1 \sigma_2 \rho \varphi (\beta \gamma + \lambda) (\eta_1 b + \eta_2 e)}{a (\gamma + \lambda) \left[ \pi_1 \sigma_2 (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \varepsilon \sigma_1 + \alpha \varepsilon \sigma_1 \sigma_2 \right]}, & \mathcal{R}_8 &= \frac{\varphi \eta_3 \varepsilon \sigma_1 \sigma_2 \rho \psi}{\delta (\psi + \omega) \left[ \pi_1 \sigma_2 (\eta_1 b + \eta_2 e) + \pi_2 \eta_3 \varepsilon \sigma_1 + \alpha \varepsilon \sigma_1 \sigma_2 \right]},
\end{align*}
\]

According to the above discussion, we sum up the existence conditions for all equilibria in Table 2.

5. Global stability analysis

In this section we prove the global asymptotic stability of all equilibria by constructing Lyapunov functional following the method presented in [50]. We will use the arithmetic-geometric mean inequality
\[
\frac{1}{n} \sum_{i=1}^{n} \chi_i \geq \sqrt[n]{\prod_{i=1}^{n} \chi_i}, \quad \chi_i \geq 0, \quad i = 1, 2, ...
\]
which yields
\[
\frac{S_j}{S} + \frac{S IL_j}{S j L} + \frac{L I_j}{L j} \geq 3, \quad j = 1, 3, 5, 6, 7,
\]
(5.1)
Table 2. Model (2.1) equilibria and their existence conditions.

| Equilibrium point | Definition                                                                 | Existence conditions |
|-------------------|---------------------------------------------------------------------------|----------------------|
| D₀ = (S₀, 0, 0, 0, 0, 0, 0) | Infection-free equilibrium                                                  | None                 |
| D₁ = (S₁, L₁, I₁, 0, 0, V₁, 0, 0) | Chronic HIV mono-infection equilibrium with inactive immune response        | ℜ₁ > 1               |
| D₂ = (S₂, 0, 0, E₂, Y₂, 0, 0, 0) | Chronic HTLV mono-infection equilibrium with inactive immune response       | ℜ₂ > 1               |
| D₃ = (S₃, L₃, I₃, 0, 0, V₃, C₃', 0) | Chronic HIV mono-infection equilibrium with only active HIV-specific CTL     | ℜ₃ > 1               |
| D₄ = (S₄, 0, 0, E₄, Y₄, 0, 0, C₄') | Chronic HTLV mono-infection equilibrium with only active HTLV-specific CTL  | ℜ₄ > 1               |
| D₅ = (S₅, L₅, I₅, E₅, V₅, C₅', 0) | Chronic HIV/HTLV co-infection equilibrium with only active HIV-specific CTL | ℜ₅ > 1 and ℜ₁/ℜ₂ > 1 |
| D₆ = (S₆, L₆, I₆, E₆, V₆, 0, 0, C₆') | Chronic HIV/HTLV co-infection equilibrium with only active HTLV-specific CTL | ℜ₆ > 1 and ℜ₂/ℜ₁ > 1 |
| D₇ = (S₇, L₇, I₇, E₇, V₇, C₇', C₇') | equilibrium with active HIV-specific CTL and HTLV-specific CTL              | ℜ₇ > 1 and ℜ₈ > 1    |

\[ \begin{align*}
S_j + S VL_j &= \frac{IV_j}{S_j V_j I} \geq 3, \quad j = 1, 3, 5, 6, 7, \quad (5.2) \\
S_j + S VL_j &= \frac{L_j}{S_j V_j L} + \frac{IV_j}{L_j I} \geq 4, \quad j = 1, 3, 5, 6, 7, \quad (5.3) \\
S_j + SYE_j &= \frac{EY_j}{S_j Y E} \geq 3, \quad j = 2, 4, 5, 6, 7. \quad (5.4)
\end{align*} \]

Theorem 1. If ℜ₁ ≤ 1 and ℜ₂ ≤ 1, then D₀ is globally asymptotically stable (G.A.S).

Proof. We construct a Lyapunov function \( \Phi_0(S, L, I, E, Y, V, C^I, C^Y) \) as:

\[ \Phi_0 = S_0 F \left( S_0 \right) + \frac{\lambda}{\beta \gamma + \lambda} L + \frac{\gamma + \lambda}{\beta \gamma + \lambda} I + \frac{1}{\phi} E + \frac{\psi + \omega}{\phi \psi} Y + \frac{\eta_1 S_0}{\epsilon} V + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} C^I + \frac{\mu_2 (\psi + \omega)}{\phi \psi \sigma_2} C^Y, \]

where,

\[ F(\nu) = \nu - 1 - \ln \nu. \]

Clearly, \( \Phi_0(S, L, I, E, Y, V, C^I, C^Y) \) > 0 for all \( S, L, I, E, Y, V, C^I, C^Y > 0 \), and \( \Phi_0(S_0, 0, 0, 0, 0, 0, 0, 0) = 0 \). Calculating \( \frac{d\Phi_0}{dt} \) along the solutions of system (2.1) as:

\[ \frac{d\Phi_0}{dt} = \left(1 - \frac{S_0}{S}\right) \left[ \mu - \alpha S - \eta_1 S V - \eta_2 S I - \eta_3 S Y \right] + \frac{\lambda}{\beta \gamma + \lambda} \left[ (1 - \beta) (\eta_1 S V + \eta_2 S I) - (\lambda + \gamma) L \right] \]
\[ + \frac{\gamma + \lambda}{\beta \gamma + \lambda} \left[ \beta (\eta_1 S V + \eta_2 S I) + \lambda L - \alpha I - \mu_1 C^I \right] + \frac{1}{\phi} \left[ \phi \eta_3 S Y - (\psi + \omega) E \right] \]
\[ + \frac{\psi + \omega}{\phi \psi} \left[ \psi E - \delta Y - \mu_2 C^Y \right] + \frac{\eta_1 S_0}{\epsilon} (b I - \epsilon V) + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} \left[ \sigma_1 C^I - \pi_1 C^I \right] \]
\[ + \frac{\mu_2 (\psi + \omega)}{\phi \psi \sigma_2} \left[ \sigma_2 C^Y - \pi_2 C^Y \right]. \]
\[
= \left(1 - \frac{S_0}{S}\right)\left(\rho - \alpha S\right) + \eta_2 S_0 I + \eta_3 S_0 Y - \frac{a(\gamma + \lambda)}{\beta \gamma + \lambda} I - \frac{\delta(\psi + \omega)}{\varphi \psi} Y + \frac{\eta_1 b S_0}{\varepsilon} I - \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} C^l - \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi \psi \sigma_2} C^\gamma.
\]

Using \(S_0 = \rho/\alpha\), we obtain
\[
d\Phi_0 \over dt = -\alpha \frac{(S - S_0)^2}{S} + \frac{a(\gamma + \lambda)}{\beta \gamma + \lambda} (\mathcal{R}_1 - 1) + \frac{\delta(\psi + \omega)}{\varphi \psi} (\mathcal{R}_2 - 1) Y - \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} C^l - \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi \psi \sigma_2} C^\gamma.
\]

Therefore, \(\frac{d\Phi_0}{dt} \leq 0\) for all \(S, I, Y, C^l, C^\gamma > 0\) and \(\frac{d\Phi_0}{dt} = 0\) when \(S = S_0\) and \(I = Y = C^l = C^\gamma = 0\). Define \(\mathcal{Y}_0 = \{(S, L, I, E, Y, V, C^l, C^\gamma) : \frac{d\Phi_0}{dt} = 0\}\) and let \(\mathcal{Y}_0'\) be the largest invariant subset of \(\mathcal{Y}_0\). The solutions of system (2.1) converge to \(\mathcal{Y}_0'\). The set \(\mathcal{Y}_0'\) includes elements with \(S = S_0\) and \(I = Y = C^l = C^\gamma = 0\), and hence \(\tilde{S} = \tilde{Y} = 0\). The first and fifth equations of system (2.1) yield
\[
0 = \dot{\tilde{S}} = \rho - \alpha S_0 - \eta_1 S_0 V,
0 = \dot{\tilde{Y}} = \psi E.
\]

Thus, \(V(t) = E(t) = 0\) for all \(t\). In addition, we have \(\dot{I} = 0\) and from the third equation of system (2.1) we obtain
\[
0 = \dot{I} = \lambda L,
\]

which yields \(L(t) = 0\) for all \(t\). Therefore, \(\mathcal{Y}_0' = \{D_0\}\) and by applying Lyapunov-LaSalle asymptotic stability theorem [51–53] we get that \(D_0\) is G.A.S. \(\square\)

**Theorem 2.** Let \(\mathcal{R}_1 > 1, \mathcal{R}_2/\mathcal{R}_1 \leq 1\) and \(\mathcal{R}_3 \leq 1\), then \(D_1\) is G.A.S.

**Proof.** Define a function \(\Phi_1(S, L, I, E, Y, V, C^l, C^\gamma)\) as:
\[
\Phi_1 = S \int F \left(\frac{S}{S_1}\right) + \frac{\lambda}{\beta \gamma + \lambda} L \int F \left(\frac{L}{L_1}\right) + \frac{\gamma + \lambda}{\beta \gamma + \lambda} I \int F \left(\frac{I}{I_1}\right) + \frac{1}{\varphi} E + \frac{\psi + \omega}{\varphi \psi} Y + \frac{\eta_1 S_1}{\varepsilon} V \int F \left(\frac{V}{V_1}\right) + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} C^l + \frac{\mu_2 (\psi + \omega)}{\varphi \psi \sigma_2} C^\gamma.
\]

Calculating \(\frac{d\Phi_1}{dt}\) as:
\[
\frac{d\Phi_1}{dt} = \left(1 - \frac{S_1}{S}\right)\left[\rho - \alpha S - \eta_1 S V - \eta_2 S I - \eta_3 S Y\right] + \frac{\lambda}{\beta \gamma + \lambda} \left(1 - \frac{L_1}{L}\right)\left[\left(1 - \beta\right)(\eta_1 S V + \eta_2 S I) - (\lambda + \gamma) L\right] + \frac{\gamma + \lambda}{\beta \gamma + \lambda} \left(1 - \frac{I_1}{I}\right)\left[\beta(\eta_1 S V + \eta_2 S I) + \lambda L - \mu_1 C^l I\right] + \frac{1}{\varphi} \left[\varphi \eta_1 S Y - (\psi + \omega) E\right] + \frac{\psi + \omega}{\varphi \psi} \left[\psi E - \delta Y - \mu_2 C^\gamma Y\right] + \frac{\eta_1 S_1}{\varepsilon} \left(1 - \frac{V_1}{V}\right)\left[b I - \varepsilon V\right] + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} \left[\sigma_1 C^l I - \pi_1 C^l I\right]
\]
\[
\begin{align*}
\Phi &= \frac{\mu_2(\psi + \omega)}{\phi \sigma_2} \left[ \sigma_2 C^\gamma Y - \pi_2 C^\gamma \right] \\
&= \left(1 - \frac{S_1}{S}\right) (\rho - \alpha S) + \eta S_1 I + \eta S_1 Y - \frac{(1 - \beta)}{\beta y + \lambda} (\eta S_1 V + \eta S_1 I) \frac{L_1}{L} \\
&+ \frac{\lambda (y + \lambda)}{\beta y + \lambda} I_1 - \frac{a(y + \lambda)}{\beta y + \lambda} - \frac{\beta(y + \lambda)}{\beta y + \lambda} (\eta S_1 V + \eta S_1 I) \frac{I_1}{I} - \frac{(1 - \beta)}{\beta y + \lambda} \frac{L_1}{L} \\
&+ \frac{a(y + \lambda)}{\beta y + \lambda} I_1 + \frac{\mu_1 (y + \lambda)}{\beta y + \lambda} C I - \frac{\delta(\psi + \omega)}{\phi \sigma} Y + \eta S_1 \frac{b I}{\varepsilon} - \eta S_1 \frac{b I V}{\varepsilon} \\
&+ \eta S_1 V_1 - \frac{\mu_1 \pi_1 (y + \lambda)}{\sigma_1 (\beta y + \lambda)} C I - \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \sigma_2} C^\gamma.
\end{align*}
\]

Using the equilibrium conditions for D1, we get
\[
\rho = \alpha S_1 + \eta S_1 V_1 + \eta S_1 I_1, \quad \frac{(1 - \beta)}{\beta y + \lambda} = \frac{(y + \lambda)}{\beta y + \lambda},
\]
\[
\eta S_1 V_1 + \eta S_1 I_1 = \frac{a(y + \lambda)}{\beta y + \lambda} I_1, \quad V_1 = \frac{b I_1}{\varepsilon}.
\]

Then, we obtain
\[
\frac{d\Phi_1}{dt} = \left(1 - \frac{S_1}{S}\right) (\alpha S_1 - S) + (\eta S_1 V_1 + \eta S_1 I_1) \left(1 - \frac{S_1}{S}\right) + \eta S_1 Y - \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta S_1 V_1 \frac{S V L_1}{S V S_1 L_1} \\
- \frac{(1 - \beta)}{\beta y + \lambda} \eta S_1 I_1 \frac{S I L_1}{S I S_1 L_1} + \frac{(1 - \beta)}{\beta y + \lambda} (\eta S_1 V_1 + \eta S_1 I_1) - \frac{\beta (y + \lambda)}{\beta y + \lambda} \eta S_1 V_1 \frac{S V L_1}{S V S_1 L_1} \\
- \frac{\beta (y + \lambda)}{\beta y + \lambda} \eta S_1 I_1 \frac{S I L_1}{S I S_1 L_1} - \frac{(1 - \beta)}{\beta y + \lambda} (\eta S_1 V_1 + \eta S_1 I_1) \frac{S V L_1}{S V S_1 L_1} + \eta S_1 V_1 + \eta S_1 I_1 + \frac{\mu_1 (y + \lambda)}{\beta y + \lambda} C I_1 \\
- \frac{\delta(\psi + \omega)}{\phi \sigma} Y + \eta S_1 V_1 \frac{S V L_1}{S V S_1 L_1} + \eta S_1 I_1 - \frac{\mu_1 \pi_1 (y + \lambda)}{\sigma_1 (\beta y + \lambda)} C I - \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \sigma_2} C^\gamma \\
= -\alpha \frac{(S - S_1)^2}{S} + \frac{(1 - \beta)}{\beta y + \lambda} \eta S_1 V_1 \left(4 - \frac{S_1}{S} - \frac{S V L_1}{S V S_1 L_1} - \frac{L_1}{L_1} - \frac{I V_1}{I V_1}\right) \\
+ \frac{(1 - \beta)}{\beta y + \lambda} \eta S_1 I_1 \left(3 - \frac{S_1}{S} - \frac{S I L_1}{S I S_1 L_1} - \frac{L_1 I}{L_1 I}\right) + \frac{\beta (y + \lambda)}{\beta y + \lambda} \eta S_1 V_1 \left(3 - \frac{S_1}{S} - \frac{S V L_1}{S V S_1 I_1} - \frac{I V_1}{I V_1}\right) \\
+ \frac{\beta (y + \lambda)}{\beta y + \lambda} \eta S_1 I_1 \left(2 - \frac{S_1}{S} - \frac{S}{S_1}\right) + \frac{\delta(\psi + \omega)}{\phi \sigma} \left(\frac{\eta S_1 \phi_3 S_1}{\delta(\psi + \omega)} - 1\right) Y \\
+ \frac{\mu_1 (y + \lambda)}{\beta y + \lambda} \left(1 - \frac{\pi_1}{\sigma_1}\right) C I - \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \sigma_2} C^\gamma.
\]

Therefore, Eq (5.5) becomes
\[
\frac{d\Phi_1}{dt} = -\left(\alpha + \frac{\beta \eta S_1 I_1 (y + \lambda)}{\beta y + \lambda}\right) \frac{(S - S_1)^2}{S} + \frac{(1 - \beta)}{\beta y + \lambda} \eta S_1 V_1 \left(4 - \frac{S_1}{S} - \frac{S V L_1}{S V S_1 I_1} - \frac{L_1 I}{L_1 I} - \frac{I V_1}{I V_1}\right) \\
+ \frac{(1 - \beta)}{\beta y + \lambda} \eta S_1 I_1 \left(3 - \frac{S_1}{S} - \frac{S I L_1}{S I S_1 L_1} - \frac{L_1 I}{L_1 I}\right) + \frac{\beta (y + \lambda)}{\beta y + \lambda} \eta S_1 V_1 \left(3 - \frac{S_1}{S} - \frac{S V L_1}{S V S_1 I_1} - \frac{I V_1}{I V_1}\right) \\
+ \frac{\delta(\psi + \omega)}{\phi \sigma} \left(R_2 / R_1 - 1\right) Y + \frac{\mu_1 (y + \lambda) [\pi_1 (\eta S_1 b + \eta S_2 e) + \alpha e \sigma_1]}{\sigma_1 (\beta y + \lambda) (\eta S_1 b + \eta S_2 e)} \left(R_3 - 1\right) C I - \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \sigma_2} C^\gamma.
\]
Since $\mathcal{R}_2/\mathcal{R}_1 \leq 1$ and $\mathcal{R}_3 \leq 1$, then using inequalities (5.1)–(5.3) we get $\frac{d\Phi_1}{dt} \leq 0$ for all $S, L, I, Y, Y, C, C'$. Moreover, $\frac{d\Phi_1}{dt} = 0$ when $S = S_1$, $L = L_1$, $I = I_1$, $V = V_1$ and $Y = C' = C'' = 0$. The solutions of system (2.1) converge to $\mathcal{Y}_1$ the largest invariant subset of $\mathcal{Y}_1 = \{(S, L, I, E, Y, V, C, C') : \frac{d\Phi_1}{dt} = 0\}$. The set $\mathcal{Y}_1$ includes $Y = 0$, and then $\dot{Y} = 0$. The fifth equation of system (2.1) implies

$$0 = \dot{Y} = \phi Y,$$

which yields $E(t) = 0$ for all $t$. Hence, $\mathcal{Y}_1 = \{\mathcal{D}_1\}$ and $\mathcal{D}_1$ is G.A.S using Lyapunov-LaSalle asymptotic stability theorem. □

**Theorem 3.** If $\mathcal{R}_2 > 1$, $\mathcal{R}_1/\mathcal{R}_2 \leq 1$ and $\mathcal{R}_3 \leq 1$, then $\mathcal{D}_2$ is G.A.S.

**Proof.** We define $\Phi_2(S, L, I, E, Y, V, C', C'')$ as:

$$\Phi_2 = S \Phi \left( \frac{S}{S_2} \right) + \frac{\lambda}{\beta Y + \lambda} L + \frac{\gamma + \lambda}{\beta Y + \lambda} I + \frac{1}{E_2} E_2 + \frac{\psi + \omega}{\phi \psi} \eta Y \Phi \left( \frac{Y}{Y_2} \right) + \frac{\eta S_2}{\epsilon} + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta' + \lambda)} C' + \frac{\mu_2 (\psi + \omega)}{\phi \psi \sigma_2} C''.$$

We calculate $\frac{d\Phi_2}{dt}$ as:

$$\frac{d\Phi_2}{dt} = \left(1 - \frac{S_2}{S}\right) \left[\rho - \alpha S - \eta S V - \eta S I - \eta S Y\right] + \frac{\lambda}{\beta Y + \lambda} \left[(1 - \beta) (\eta S V + \eta S I) - (\lambda + \gamma) L\right] + \frac{\gamma + \lambda}{\beta Y + \lambda} \left[\beta (\eta S V + \eta S I) + \lambda L - \alpha I - \mu C' I\right] + \frac{1}{\phi} \left[\psi Y - \phi Y - \mu_2 C' Y\right] + \frac{\psi + \omega}{\phi \psi} \left(1 - \frac{Y}{Y_2}\right) \left[\psi E - \delta Y - \mu_2 C' Y\right] + \frac{\eta S_2}{\epsilon} \left[b I - \phi E\right] + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta' + \lambda)} \left[\sigma_1 C' I - \pi I C''\right] + \frac{\mu_2 (\psi + \omega)}{\phi \psi \sigma_2} \left[\sigma_2 C' Y - \pi_2 C''\right].$$

Using the equilibrium conditions for $\mathcal{D}_2$:

$$\rho = \alpha S + \eta S^2 Y, \quad \eta S Y = \frac{\psi + \omega}{\phi} E_2 = \frac{\delta (\psi + \omega)}{\phi} Y_2,$$

we obtain

$$\frac{d\Phi_2}{dt} = \left(1 - \frac{S_2}{S}\right) (\rho - \alpha S - \eta S Y) + \eta S_2 Y \left(1 - \frac{S_2}{S}\right) + \eta S_2 I - \frac{\alpha (\gamma + \lambda)}{\beta Y + \lambda} I - \eta S_2 Y^2 \frac{S Y E_2}{S_2 Y^2} + \eta S_2 Y^2$$

$$- \eta S_2 Y \frac{E Y_2}{E_2 Y} + \eta S_2 Y + \frac{\mu_2 (\psi + \omega)}{\phi \psi} C' Y_2 + \eta S_2 \frac{b I}{\epsilon} - \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta' + \lambda)} C' + \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \psi \sigma_2} C'$$

$$- \frac{(S - S_2)^2}{S} + \eta S_2 Y \left(3 - \frac{S_2}{S} - \frac{S Y E_2}{S_2 Y^2} - \frac{E Y_2}{E_2 Y}\right) + \frac{a (\gamma + \lambda)}{\beta Y + \lambda} \left[\eta b + \eta c \right] \frac{S_2}{a e (\gamma + \lambda)}.$$
From conditions (5.7) we get\( V \) from equation of system (2.1) gives system (2.1) converge to 0. In addition,\( \alpha \left( \frac{S - S_2}{S} \right) + \eta_3 S_2 Y_2 \left( 3 - \frac{S}{S_2} - \frac{SY_2}{S_2 Y_2 E} - \frac{EY_2}{E_2 Y} + \frac{a (\gamma + \lambda)}{\beta \gamma + \lambda} \right) \left( \mathcal{R}_1 / \mathcal{R}_2 - 1 \right) I \)\( - \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\gamma + \lambda)} C^I + \frac{\mu_2 (\psi + \omega)}{\varphi \psi} \left( Y_2 - \frac{\varpi_2}{\sigma_2} \right) C^Y \)

Since \( \mathcal{R}_1 / \mathcal{R}_2 \leq 1 \) and \( \mathcal{R}_4 \leq 1 \), then using inequality (5.4) we get \( \frac{d\rho}{dt} \leq 0 \) for all \( S, L, I, E, Y, V, C^I, C^Y > 0 \). In addition, \( \frac{d\rho}{dt} = 0 \) when \( S = S_2, E = E_2, Y = Y_2, I = C^I = C^Y = 0 \). Define \( \mathcal{Y}_2 = \{ (S, L, I, E, Y, V, C^I, C^Y) : \frac{d\rho}{dt} = 0 \} \) and let \( \mathcal{Y}'_2 \) be the largest invariant subset of \( \mathcal{Y}_2 \). The solutions of system (2.1) converge to \( \mathcal{Y}'_2 \) which includes elements with \( S = S_2, Y = Y_2, I = 0, \) then \( S = 0 \). The first equation of system (2.1) gives

\[
\dot{S} = \rho - \alpha S - \eta_1 S_2 V - \eta_3 S_2 Y_2.
\]

From conditions (5.7) we get \( V(t) = 0 \) for all \( t \). Moreover, we have \( I = 0 \) and from the third equation of system (2.1) we obtain

\[
0 = \dot{I} = \lambda L,
\]

which yields \( L(t) = 0 \) for all \( t \). Therefore, \( \mathcal{Y}'_2 = \{ \mathcal{D}_2 \} \). By applying Lyapunov-LaSalle asymptotic stability theorem we get that \( \mathcal{D}_2 \) is G.A.S. \( \square \)

**Theorem 4.** Let \( \mathcal{R}_3 > 1 \) and \( \mathcal{R}_2 \leq 1 \), then \( \mathcal{D}_3 \) is G.A.S.

**Proof.** Define a function \( \Phi_3(S, L, I, E, Y, V, C^I, C^Y) \) as:

\[
\Phi_3 = S F \left( \frac{S}{S_3} \right) + \frac{\lambda}{\beta \gamma + \lambda} L_3 F \left( \frac{L}{L_3} \right) + \frac{\gamma + \lambda}{\beta \gamma + \lambda} I_3 F \left( \frac{I}{I_3} \right) + \frac{1}{\varphi} E + \frac{\psi + \omega}{\varphi \psi} Y + \eta_1 S_2 \frac{V}{V_3} F \left( \frac{V}{V_3} \right) + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\gamma + \lambda)} C^I F \left( \frac{C^I}{C^I_3} \right) + \frac{\mu_2 (\psi + \omega)}{\varphi \psi \sigma_2} C^Y.
\]

We calculate \( \frac{d\Phi_3}{dt} \) as:

\[
\frac{d\Phi_3}{dt} = \left( 1 - \frac{S_3}{S} \right) [\rho - \alpha S - \eta_1 S V - \eta_2 S I - \eta_3 S Y] + \frac{\lambda}{\beta \gamma + \lambda} \left( 1 - \frac{L_3}{L} \right) \left( (1 - \beta) (\eta_1 S V + \eta_2 S I) - (\lambda + \gamma) L \right) + \frac{\gamma + \lambda}{\beta \gamma + \lambda} \left( 1 - \frac{I_3}{I} \right) \left( \beta (\eta_1 S V + \eta_3 S Y) + \lambda L - a I - \mu_1 C^I \right) + \frac{1}{\varphi} \left( \varphi \eta_3 S Y - (\psi + \omega) E \right) + \frac{\psi + \omega}{\varphi \psi} \left[ \psi E - \eta_2 \frac{C^I}{C^I_3} \right] + \eta_1 S_2 \left( 1 - \frac{V}{V_3} \right) \left[ b I - \varphi Y \right] + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\gamma + \lambda)} \left( 1 - \frac{C^I_3}{C^I} \right) \left( \sigma_1 C^I I - \pi_1 C^I \right) + \frac{\mu_2 (\psi + \omega)}{\varphi \psi \sigma_2} \left[ \sigma_2 C^Y Y - \pi_2 C^Y \right] = \left( 1 - \frac{S_3}{S} \right) [\rho - \alpha S] + \eta_2 S_3 I + \eta_3 S_3 Y - \frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} (\eta_1 S V + \eta_2 S I) \frac{L_3}{L} + \frac{\lambda (\gamma + \lambda)}{\beta \gamma + \lambda} \frac{L_3}{L_3} - \frac{\alpha (\gamma + \lambda)}{\beta \gamma + \lambda} I - \frac{\beta (\gamma + \lambda)}{\beta \gamma + \lambda} (\eta_1 S V + \eta_2 S I) \frac{L_3}{L} + \frac{\alpha (\gamma + \lambda)}{\beta \gamma + \lambda} I_3.
\]
Using the equilibrium conditions for $D_3$:

$$\rho = a S_3 + \eta_1 S_3 V_3 + \eta_2 S_3 I_3, \quad \frac{\lambda (1 - \beta)}{\beta y + \lambda} (\eta_1 S_3 V_3 + \eta_2 S_3 I_3) = \frac{\lambda (y + \lambda)}{\beta y + \lambda} L_3,$$

$$\eta_1 S_3 V_3 + \eta_2 S_3 I_3 = \frac{a (y + \lambda)}{\beta y + \lambda} I_3 + \frac{\mu_1 (y + \lambda)}{\beta y + \lambda} C_2 I_3, \quad I_3 = \frac{\pi_1}{\sigma_1}, \quad V_3 = \frac{b}{\epsilon} I_3,$$

we obtain

$$\frac{d \Phi_3}{dt} = \left(1 - \frac{S_3}{S}\right) \left(\alpha S_3 - a S\right) + \left(\eta_1 S_3 V_3 + \eta_2 S_3 I_3\right) \left(1 - \frac{S_3}{S}\right) + \left(\eta_3 S_3 - \delta (\psi + \omega) \right) Y$$

$$- \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_1 S_3 V_3 \frac{SVL_3}{S_3 V_3 L} - \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_2 S_3 I_3 \frac{SIL_3}{S_3 I_3 L} + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \left(\eta_1 S_3 V_3 + \eta_2 S_3 I_3\right)$$

$$- \frac{\beta y + \lambda}{\beta y + \lambda} \eta_1 S_3 V_3 \frac{S V I_3}{S_3 S_3 I_3} - \frac{\beta y + \lambda}{\beta y + \lambda} \eta_2 S_3 I_3 \frac{S}{S_3} - \frac{\lambda (1 - \beta)}{\beta y + \lambda} \left(\eta_1 S_3 V_3 + \eta_2 S_3 I_3\right) \frac{LI_3}{L_3 I}$$

$$+ \eta_1 S_3 V_3 + \eta_2 S_3 I_3 - \eta_1 S_3 V_3 \frac{IV_3}{I_3 V} + \eta_1 S_3 V_3 - \frac{\mu_2 \pi_2 (\psi + \omega) C^}\gamma}{\varphi \psi \sigma_2}$$

$$= -a \left(\frac{S - S_3}{S}\right)^2 + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_1 S_3 V_3 \left(4 - \frac{S_3}{S}\right) - \frac{SVL_3}{S_3 V_3 L} - \frac{LI_3}{L_3 I} - \frac{IV_3}{I_3 V}$$

$$+ \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_2 S_3 I_3 \left(3 - \frac{S_3}{S}\right) - \frac{SIL_3}{S_3 I_3 L} - \frac{LI_3}{L_3 I} + \frac{\beta y + \lambda}{\beta y + \lambda} \eta_1 S_3 V_3 \left(3 - \frac{S_3}{S}\right) - \frac{S V I_3}{S_3 S_3 I_3} - \frac{IV_3}{I_3 V}$$

$$+ \frac{\beta y + \lambda}{\beta y + \lambda} \eta_2 S_3 I_3 \left(2 - \frac{S_3}{S}\right) - \frac{S}{S_3} - \frac{\delta (\psi + \omega)}{\varphi \psi \sigma_2} Y - \frac{\mu_2 \pi_2 (\psi + \omega) C^}\gamma}{\varphi \psi \sigma_2}$$

$$= -a \left(\frac{S - S_3}{S}\right)^2 + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_1 S_3 V_3 \left(4 - \frac{S_3}{S}\right) - \frac{SVL_3}{S_3 V_3 L} - \frac{LI_3}{L_3 I} - \frac{IV_3}{I_3 V}$$

$$+ \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_2 S_3 I_3 \left(3 - \frac{S_3}{S}\right) - \frac{SIL_3}{S_3 I_3 L} - \frac{LI_3}{L_3 I} + \frac{\beta y + \lambda}{\beta y + \lambda} \eta_1 S_3 V_3 \left(3 - \frac{S_3}{S}\right) - \frac{S V I_3}{S_3 S_3 I_3} - \frac{IV_3}{I_3 V}$$

$$+ \frac{\beta y + \lambda}{\beta y + \lambda} \eta_2 S_3 I_3 \left(2 - \frac{S_3}{S}\right) - \frac{S}{S_3} - \frac{\delta (\psi + \omega)}{\varphi \psi \sigma_2} Y - \frac{\mu_2 \pi_2 (\psi + \omega) C^}\gamma}{\varphi \psi \sigma_2}.$$
which yield $C'(t) = C_3'$ and $E(t) = 0$ for all $t$. Therefore, $\gamma_3' = \{D_3\}$. By applying Lyapunov-LaSalle asymptotic stability theorem we get that $D_3$ is G.A.S.

**Theorem 5.** If $R_4 > 1$ and $R_6 \leq 1$, then $D_4$ is G.A.S.

**Proof.** Define $\Phi_4(S, L, I, E, Y, V, C', C^Y)$ as:

$$
\Phi_4 = S_4 F \left( \frac{S}{S_4} \right) + \frac{\lambda}{\beta Y + \lambda} L + \frac{\gamma + \lambda}{\beta Y + \lambda} I + \frac{1}{\varphi} E_4 F \left( \frac{E}{E_4} \right) + \frac{\psi + \omega}{\varphi \psi} Y_4 F \left( \frac{Y}{Y_4} \right) + \frac{\eta_1 S_4}{\varepsilon} V + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta Y + \lambda)} C' + \frac{\mu_2 (\psi + \omega)}{\varphi \psi \sigma_2} C^Y_4 F \left( \frac{C^Y}{C^Y_4} \right).
$$

Calculating $\frac{d\Phi_4}{dt}$ as:

$$
\frac{d\Phi_4}{dt} = \left(1 - \frac{S_4}{S}\right) [\rho - \alpha S - \eta_1 S V - \eta_2 S I - \eta_3 S Y] + \frac{\lambda}{\beta Y + \lambda} [(1 - \beta) (\eta_1 S V + \eta_2 S I) - (\lambda + \gamma) L]
$$

$$
+ \frac{\gamma + \lambda}{\beta Y + \lambda} [\beta (\eta_1 S V + \eta_2 S I) + \lambda L - a I - \mu_1 C'I] + \frac{1}{\varphi} \left(1 - \frac{E}{E_4}\right) \left[\varphi \eta_3 S Y - (\psi + \omega) E\right]
$$

$$
+ \frac{\psi + \omega}{\varphi \psi} \left(1 - \frac{Y}{Y_4}\right) \left[\varphi E - \delta Y - \mu_2 C^Y\right] + \frac{\eta_1 S_4}{\varepsilon} [b I - \varepsilon V]
$$

$$
+ \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta Y + \lambda)} \left[\sigma_1 C'I - \pi_1 C'\right] + \frac{\mu_2 (\psi + \omega)}{\varphi \psi \sigma_2} \left(1 - \frac{C^Y_4}{C^Y}\right) \left[\sigma_2 C^Y Y - \pi_2 C^Y\right]
$$

$$
= \left(1 - \frac{S_4}{S}\right) [\rho - \alpha S] + \eta_2 S_4 I + \eta_3 S_4 Y - \frac{a (\gamma + \lambda)}{\beta Y + \lambda} I + \frac{\psi + \omega}{\varphi} E_4 + \frac{\psi + \omega}{\varphi} Y_4
$$

$$
- \frac{\delta (\psi + \omega)}{\psi \varphi} Y - \frac{\psi + \omega}{\varphi} E_4 Y_4 + \frac{\delta (\psi + \omega)}{\varphi \psi} Y_4 + \frac{\mu_2 (\psi + \omega)}{\varphi \psi} C^Y_4 Y + \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta Y + \lambda)} C' - \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi \psi} C^Y_4 + \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi \psi \sigma_2} C^Y_4 Y.
$$

Using the equilibrium conditions for $D_4$:

$$
\rho = \alpha S_4 + \eta_3 S_4 Y_4, \quad Y_4 = \frac{\pi_2}{\sigma_2},
$$

$$
\eta_3 S_4 Y_4 = \frac{\psi + \omega}{\varphi} E_4 = \frac{\delta (\psi + \omega)}{\varphi} Y_4 + \frac{\mu_2 (\psi + \omega)}{\varphi \psi} C^Y_4 Y_4.
$$

We obtain

$$
\frac{d\Phi_4}{dt} = \left(1 - \frac{S_4}{S}\right) [\alpha S - \alpha S] + \eta_3 S_4 Y_4 \left(1 - \frac{S_4}{S}\right) + \frac{\eta_2 S_4 I}{\beta Y + \lambda} + \frac{\psi + \omega}{\varphi \psi} Y_4 + \frac{\eta_1 S_4}{\varepsilon} V + \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta Y + \lambda)} C'
$$

$$
= -\alpha \frac{(S - S_4)^2}{S} + \eta_3 S_4 Y_4 \left(3 - \frac{S_4}{S}\right) - \frac{S Y E_4}{S_4 Y_4 E} - \frac{E Y_4}{S_4 Y_4 E} + \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta Y + \lambda)} C'.
$$

**AIMS Mathematics**

**Volume 6, Issue 2, 1634–1676.**
\[ = -a \left( S - S_e \right)^2 + \eta_1 S_e Y_4 \left( 3 - \frac{S E_4}{S} - \frac{S Y E_4}{S Y_4} - \frac{E Y_4}{E_4 Y} \right) + \frac{a \left( \gamma + \lambda \right)}{\beta \gamma + \lambda} \left( R_6 - 1 \right) I - \frac{\mu_1 \pi_1 \left( \gamma + \lambda \right)}{\sigma_1 \left( \beta \gamma + \lambda \right)} C^I. \]

If \( R_6 \leq 1 \), then using inequality (5.4) we get \( \frac{d \Phi_5}{dt} \leq 0 \) for all \( S, L, I, E, Y, V, C', C^Y > 0 \), where \( \frac{d \Phi_4}{dt} = 0 \) at \( S = S_4, E = E_4, Y = Y_4 \) and \( I = C' = 0 \). The solutions of system (2.1) converge to \( Y'_4 \) the largest invariant subset of \( Y_4 = \{ (S, L, I, E, Y, V, C', C^Y) \} : \frac{d \Phi_4}{dt} = 0 \}. \) The set \( Y'_4 \) contains elements with \( S = S_4, E = E_4, Y = Y_4, I = 0 \), and then \( S = \dot{Y} = 0 \). The first and fifth equations of system (2.1) imply

\[
0 = \dot{S} = \rho - \alpha S_4 - \eta_1 S_4 V - \eta_3 S_4 Y_4,
\]

\[
0 = \dot{Y} = \psi E_4 - \delta Y_4 - \mu_2 C^Y Y_4,
\]

which yield \( V(t) = 0 \) and \( C^Y(t) = C_4^I \) for all \( t \). Since \( I = 0 \), then from the third equation of system (2.1) we obtain

\[
0 = \dot{I} = \lambda L,
\]

which yields \( L(t) = 0 \) for all \( t \). Therefore, \( Y'_4 = \{ D_4 \} \). By applying Lyapunov-LaSalle asymptotic stability theorem we obtain that \( D_4 \) is G.A.S. \( \Box \)

**Theorem 6.** If \( R_5 > 1, R_8 \leq 1 \) and \( R_1 / R_2 > 1 \), then \( D_5 \) is G.A.S.

**Proof.** Define \( \Phi_5(S, L, I, E, Y, V, C', C^Y) \) as:

\[
\Phi_5 = S_5 F \left( \frac{S}{S_5} \right) + \frac{\lambda}{\beta \gamma + \lambda} L_5 F \left( \frac{L}{L_5} \right) + \frac{\gamma + \lambda}{\beta \gamma + \lambda} I_5 F \left( \frac{I}{I_5} \right) + \frac{1}{\varphi} F \left( \frac{E}{E_5} \right)
\]

\[
+ \frac{1}{\gamma} \frac{Y_5}{\varphi \psi} F \left( \frac{Y}{Y_5} \right) + \frac{\eta_1 S_5}{\varepsilon} V_5 F \left( \frac{V}{V_5} \right) + \frac{\mu_1 \left( \gamma + \lambda \right)}{\sigma_1 \left( \beta \gamma + \lambda \right)} C^I_5 F \left( \frac{C^I_5}{C^I} \right) + \frac{\mu_2 \left( \psi + \omega \right)}{\varphi \psi \sigma_2} C^Y.
\]

Calculating \( \frac{d \Phi_5}{dt} \) as:

\[
\frac{d \Phi_5}{dt} = \left( 1 - \frac{S_5}{S} \right) \left( \rho - \alpha S - \eta_2 S V - \eta_3 S Y - \eta_3 S I - \eta_3 S Y \right)
\]

\[
+ \frac{\lambda}{\beta \gamma + \lambda} \left( 1 - \frac{L_5}{L} \right) \left( \left( 1 - \beta \right) \left( \eta_1 S V + \eta_2 S I \right) \right) - \left( \lambda + \gamma \right) L
\]

\[
+ \left( 1 - \frac{I_5}{I} \right) \left( \left( \beta \eta_1 S V + \eta_2 S I \right) + \lambda L - a I - \mu_2 C^I \right)
\]

\[
+ \frac{1}{\varphi} \left( 1 - \frac{E_5}{E} \right) \left( \varphi_3 S Y - (\psi + \omega) E \right) + \frac{\psi + \omega}{\varphi \psi} \left( 1 - \frac{Y_5}{Y} \right) \left( \psi E - \delta Y - \mu_2 C^Y Y \right)
\]

\[
+ \frac{\eta_1 S_5}{V} \left( 1 - \frac{V_5}{V} \right) \left[ \beta I - \varepsilon V \right] + \frac{\mu_1 \left( \gamma + \lambda \right)}{\sigma_1 \left( \beta \gamma + \lambda \right)} \left( 1 - \frac{C^I_5}{C^I} \right) \left[ \sigma_1 C^I I - \pi_1 C^I \right]
\]

\[
+ \frac{\mu_2 \left( \psi + \omega \right)}{\varphi \psi \sigma_2} \left[ \sigma_2 C^Y Y - 2 \sigma_2 C^Y \right]
\]

\[
= \left( 1 - \frac{S_5}{S} \right) \left( \rho - \alpha S + \eta_2 S I + \eta_3 S Y \right) - \frac{\lambda \left( 1 - \beta \right)}{\beta \gamma + \lambda} \left( \eta_1 S V + \eta_2 S I \right) \frac{L_5}{L} + \frac{\lambda \left( \gamma + \lambda \right)}{\beta \gamma + \lambda} L_5
\]

\[
- \frac{\eta_1 S_5}{S} \frac{\eta_1 S Y}{S} - \frac{\alpha \left( \gamma + \lambda \right)}{\beta \gamma + \lambda} \left( \eta_1 S V + \eta_2 S I \right) \frac{I_5}{I} - \frac{\lambda \left( \gamma + \lambda \right)}{\beta \gamma + \lambda} I_5 + \frac{\alpha \left( \gamma + \lambda \right)}{\beta \gamma + \lambda} I_5.
\]
Then, Eq (5.8) will be reduced to the form

\[
\frac{d\Phi_5}{dt} = -\left(\alpha + \frac{\beta_2 S_5 (y + \lambda)}{\beta y + \lambda}\right) \frac{(S - S_5)^2}{S} + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta S_5 V_5 \left(4 - S_5 \frac{S}{S V_5} - S V L_5 - \frac{L I_5}{I_5 V} - \frac{I V_5}{I_5 V} \right) + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta S_5 V_5 \left(4 - S_5 \frac{S}{S V_5} - S V L_5 - \frac{L I_5}{I_5 V} - \frac{I V_5}{I_5 V} \right)
\]

Using the equilibrium conditions for \( D_5 \):

\[
\rho = \alpha S_5 + \eta_1 S_5 V_5 + \eta_2 S_5 I_5 + \eta_3 S_5 Y_5,
\]

\[
\frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta S_5 V_5 + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta S_5 V_5 \eta S_5 I_5 = \frac{\lambda (y + \lambda)}{\beta y + \lambda} \eta S_5 V_5 C_1',
\]

\[
\eta_1 S_5 V_5 + \eta_2 S_5 I_5 = \frac{a (y + \lambda)}{\beta y + \lambda} I_5 + \frac{\mu_1 (y + \lambda)}{\beta y + \lambda} C_1',
\]

\[
\eta_3 S_5 Y_5 = \frac{\psi + \omega}{\varphi} E_5 \frac{\delta (\psi + \omega)}{\varphi \psi} Y_5, \quad I_5 = \frac{\mu_1 (y + \lambda)}{\sigma_1 (y + \lambda)} C_1', \quad V_5 = \frac{b I_5}{\epsilon}.
\]

We obtain

\[
\frac{d\Phi_5}{dt} = \left(1 - \frac{S_5}{S}\right) \left(\alpha S_5 - \alpha S + (\eta_1 S_5 V_5 + \eta_2 S_5 I_5 + \eta_3 S_5 Y_5) \left(1 - \frac{S_5}{S}\right) - \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_1 S_5 V_5 + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_2 S_5 I_5 + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta_3 S_5 Y_5 \right)
\]

\[
\left(4 - S_5 \frac{S}{S V_5} - S V L_5 - \frac{L I_5}{I_5 V} - \frac{I V_5}{I_5 V} \right) + \frac{\mu_2 (\psi + \omega)}{\varphi \psi} \left(\frac{\delta (\psi + \omega)}{\varphi \psi} Y_5 - \frac{\pi_2}{\sigma_2} C_1'\right).
\]

Then, Eq (5.8) will be reduced to the form

\[
\frac{d\Phi_5}{dt} = -\left(\alpha + \frac{\beta_2 S_5 (y + \lambda)}{\beta y + \lambda}\right) \frac{(S - S_5)^2}{S} + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta S_5 V_5 \left(4 - S_5 \frac{S}{S V_5} - S V L_5 - \frac{L I_5}{I_5 V} - \frac{I V_5}{I_5 V} \right) + \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta S_5 V_5 \left(4 - S_5 \frac{S}{S V_5} - S V L_5 - \frac{L I_5}{I_5 V} - \frac{I V_5}{I_5 V} \right)
\]

\[
+ \frac{\lambda (1 - \beta)}{\beta y + \lambda} \eta S_5 V_5 \left(4 - S_5 \frac{S}{S V_5} - S V L_5 - \frac{L I_5}{I_5 V} - \frac{I V_5}{I_5 V} \right).
\]
\[ + \mu_2 (\psi + \omega) \left[ \pi_1 \sigma_2 (\eta_1 b + \eta_2 \epsilon) + \pi_2 \eta_3 \epsilon \sigma_1 + \alpha \epsilon \sigma_1 \sigma_2 \right] \frac{1}{\varphi \psi \eta_1 \epsilon \sigma_1 \sigma_2} (\mathcal{R}_8 - 1) C^\gamma. \]

If \( \mathcal{R}_8 \leq 1 \), then using inequalities (5.1)–(5.4) we get \( \frac{d\mathcal{R}_8}{dt} \leq 0 \) for all \( S, L, I, E, Y, V, C', C'' \ > 0 \), where \( \frac{d\phi_8}{dt} = 0 \) at \( S = S_5, \ L = L_5, \ I = I_5, \ E = E_5, \ Y = Y_5, \ V = V_5 \) and \( C'' = 0 \). The solutions of system (2.1) converge to \( \Gamma_5' \), the largest invariant subset of \( \Gamma_5 = \{(S, L, I, E, Y, V, C', C''): \frac{d\phi_8}{dt} = 0\} \). The set \( \Gamma_5' \) contains elements with \( S = S_5, \ L = L_5, \ I = I_5, \ V = V_5 \), and then \( \dot{I} = 0 \). Third equation of system (2.1) implies

\[ 0 = \dot{I} = \beta (\eta_1 S_5 V_5 + \eta_2 S_5 I_5) + \lambda L_5 - a I_5 - \mu_1 C'I_5, \]

which gives \( C'(t) = C'_5 \) for all \( t \). Therefore, \( \Gamma_5' = \{D_5\}. \) Applying Lyapunov-LaSalle asymptotic stability theorem we get \( D_5 \) is G.A.S. \( \square \)

**Theorem 7.** If \( \mathcal{R}_6 > 1, \ \mathcal{R}_7 \leq 1 \) and \( \mathcal{R}_2/\mathcal{R}_1 > 1 \), then \( D_6 \) is G.A.S.

**Proof.** Define \( \Phi_6(S, L, I, E, Y, V, C', C'') \) as:

\[ \Phi_6 = S_6 F \left( \frac{S}{S_6} \right) + \frac{1}{\beta \gamma + \lambda} \left( 1 - \frac{L_6}{L} \right) \left( 1 - \frac{I_6}{I} \right) \left( 1 - \frac{E_6}{E} \right) \left( 1 - \frac{Y_6}{Y} \right) \left( 1 - \frac{V_6}{V} \right) \left( 1 - \frac{C''_6}{C''} \right) \]

Calculating \( \frac{d\Phi_6}{dt} \) as:

\[ \frac{d\Phi_6}{dt} = \left( 1 - \frac{S_6}{S} \right) \left[ \rho - a S - \eta_1 S V - \eta_2 S I - \eta_3 S Y \right] \]

Adding elements with \( S = S_5, \ L = L_5, \ I = I_5, \ V = V_5 \), and then \( \dot{I} = 0 \). Third equation of system (2.1) implies

\[ 0 = \dot{I} = \beta (\eta_1 S_5 V_5 + \eta_2 S_5 I_5) + \lambda L_5 - a I_5 - \mu_1 C'I_5, \]

which gives \( C'(t) = C'_5 \) for all \( t \). Therefore, \( \Gamma_5' = \{D_5\}. \) Applying Lyapunov-LaSalle asymptotic stability theorem we get \( D_5 \) is G.A.S. \( \square \)
\[-\frac{\mu_2\pi_2 (\psi + \omega)}{\varphi \sigma_2} C^\gamma - \frac{\mu_2 (\psi + \omega)}{\varphi \psi} C^\gamma Y + \frac{\mu_2\pi_2 (\psi + \omega)}{\varphi \sigma_2} C^\gamma.\]

Using the equilibrium conditions for $D_6$:
\[
\rho = \alpha S_6 + \eta_1 S_6 V_6 + \eta_2 S_6 I_6 + \eta_3 S_6 Y_6, \\
\frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} (\eta_1 S_6 V_6 + \eta_2 S_6 I_6) = \frac{\lambda (\gamma + \lambda)}{\beta \gamma + \lambda} I_6, \quad Y_6 = \frac{\pi_2}{\sigma_2}, \quad V_6 = \frac{b I_6}{\varepsilon}, \\
\eta_1 S_6 V_6 + \eta_2 S_6 I_6 = \frac{a (\gamma + \lambda)}{\beta \gamma + \lambda} I_6, \\
\eta_3 S_6 Y_6 = \frac{\psi + \omega}{\varphi} E_6 = \frac{\delta (\psi + \omega)}{\varphi \psi} Y_6 + \frac{\mu_2 (\psi + \omega)}{\varphi \psi} C^\gamma Y_6.
\]

We obtain
\[
d\Phi_6 = \left(1 - \frac{S_6}{S}\right) (\alpha S_6 - \alpha S) + (\eta_1 S_6 V_6 + \eta_2 S_6 I_6 + \eta_3 S_6 Y_6) \left(1 - \frac{S_6}{S}\right) - \frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 \frac{S V L_6}{S_6 V_6 L} \\
- \frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} \eta_2 S_6 I_6 \frac{S I L_6}{S_6 I_6 L} + \frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} (\eta_1 S_6 V_6 + \eta_2 S_6 I_6) - \frac{\beta (\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 \frac{S V I_6}{S_6 V_6 I} \\
- \frac{\beta (\gamma + \lambda)}{\beta \gamma + \lambda} \eta_2 S_6 I_6 \frac{S}{S_6} - \frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} (\eta_1 S_6 V_6 + \eta_2 S_6 I_6) \frac{L I_6}{L_6 I} + \eta_1 S_6 V_6 + \eta_2 S_6 I_6 - \eta_3 S_6 Y_6 \frac{S Y E_6}{S_6 Y_6 E} \\
+ \eta_2 S_6 Y_6 - \eta_3 S_6 Y_6 \frac{E Y_6}{E_6 Y} + \eta_3 S_6 Y_6 - \eta_1 S_6 V_6 \frac{I V_6}{I_6 V} + \eta_1 S_6 V_6 + \mu_1 (\gamma + \lambda) \left(I_6 - \frac{\pi_1}{\sigma_1}\right) C^l.
\]

Then, Eq (5.9) will be reduced to the form
\[
d\Phi_6 = - \left(\alpha + \frac{\beta \pi_2}{\beta \gamma + \lambda} \eta_1 S_6 (\gamma + \lambda) \right) \left(\frac{S - S_6}{S}\right)^2 + \frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 \left(4 - \frac{S_6}{S} - \frac{S V L_6}{S_6 V_6 L} - \frac{L I_6}{L_6 I} - \frac{I V_6}{I_6 V}\right) \\
+ \frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} \eta_2 S_6 I_6 \left(3 - \frac{S_6}{S} - \frac{S I L_6}{S_6 I_6 L} - \frac{L I_6}{L_6 I}\right) + \frac{\beta (\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 \left(3 - \frac{S_6}{S} - \frac{S V I_6}{S_6 V_6 I} - \frac{I V_6}{I_6 V}\right) \\
+ \eta_3 S_6 Y_6 \left(3 - \frac{S_6}{S} - \frac{S Y E_6}{S_6 Y_6 E} - \frac{E Y_6}{E_6 Y}\right) + \mu_1 (\gamma + \lambda) \left[I_6 - \frac{\pi_1}{\sigma_1}\right] C^l.
\]

Therefore, if $\mathcal{R}_7 \leq 1$, then using inequalities (5.1)–(5.4) we get $\frac{d\Phi_6}{dt} \leq 0$ for all $S, L, I, E, Y, V, C^l, C^\gamma > 0$, where $\frac{d\Phi_6}{dt} = 0$ at $S = S_6, L = L_6, I = I_6, E = E_6, Y = Y_6, V = V_6$ and $C^l = 0$. Define
\( \Upsilon_6 = \{ (S, L, I, E, Y, V, C^I, C^Y) : \frac{d\Phi_6}{dt} = 0 \} \) and let \( \Upsilon'_6 \) be the largest invariant subset of \( \Upsilon_6 \). The solutions of system (2.1) tend to \( \Upsilon'_6 \) which includes elements with \( E = E_6, Y = Y_6 \), and then \( \dot{Y} = 0 \). The fifth equation of system (2.1) implies

\[
0 = \dot{Y} = \psi E_6 - \delta Y_6 - \mu_2 C^Y Y_6,
\]

which ensures that \( C^Y(t) = C^Y_0 \) for all \( t \). Therefore, \( \Upsilon'_6 = \{D_6\} \). Applying Lyapunov-LaSalle asymptotic stability theorem we get \( D_6 \) is G.A.S. □

**Theorem 8.** If \( \mathcal{R}_7 > 1 \) and \( \mathcal{R}_8 > 1 \), then \( D_7 \) is G.A.S.

**Proof.** Define \( \Phi_7(S, L, I, E, Y, V, C^I, C^Y) \) as:

\[
\Phi_7 = S_7 F \left( \frac{S}{S_7} \right) + \frac{\lambda}{\beta Y + \lambda} L_7 F \left( \frac{L}{L_7} \right) + \frac{\gamma + \lambda}{\beta Y + \lambda} I_7 F \left( \frac{I}{I_7} \right) + \frac{1}{\varphi} E_7 F \left( \frac{E}{E_7} \right) + \frac{\psi + \omega}{\varphi \psi} Y_7 F \left( \frac{Y}{Y_7} \right) + \eta_7 S_7 \frac{V}{V_7} \left( \frac{V}{V_7} \right) + \mu_1 (\gamma + \lambda) \frac{C^I}{C^I_7} + \mu_2 (\psi + \omega) C^Y_7.
\]

Calculating \( \frac{d\Phi_7}{dt} \) and after collecting terms we get

\[
\frac{d\Phi_7}{dt} = \left( 1 - \frac{S_7}{S} \right) \left( \rho - \alpha S \right) + \eta_2 S_7 I + \eta_3 S_7 Y - \frac{\lambda (1 - \beta)}{\beta Y + \lambda} (\eta_1 S V + \eta_2 S I) \frac{L_7}{L} + \frac{\lambda (Y + \gamma)}{\beta Y + \lambda} \frac{L_7}{L} - \frac{\alpha (Y + \gamma)}{\beta Y + \lambda} I - \frac{\beta (Y + \gamma)}{\beta Y + \lambda} \frac{I_7}{I} - \frac{\lambda (Y + \gamma)}{\beta Y + \lambda} \frac{L_7}{L} + \frac{\alpha (Y + \gamma)}{\beta Y + \lambda} I_7 + \frac{\mu_1 (Y + \gamma)}{\beta Y + \lambda} C^I_7 - \frac{\varphi \psi}{\varphi \psi} \frac{\delta (\psi + \omega)}{\varphi \psi} Y - \frac{\psi + \omega}{\varphi \psi} \frac{E_7}{E} - \frac{\psi + \omega}{\varphi \psi} \frac{Y_7}{Y} \frac{\varphi \psi}{\varphi \psi} \frac{\delta (\psi + \omega)}{\varphi \psi} Y + \frac{\mu_2 (\psi + \omega)}{\varphi \psi} C^Y_7.
\]

Using the equilibrium conditions for \( D_7 \):

\[
\rho = \alpha S_7 + \eta_1 S_7 V_7 + \eta_2 S_7 I_7 + \eta_3 S_7 Y_7, \quad \frac{\lambda (1 - \beta)}{\beta Y + \lambda} (\eta_1 S_7 V + \eta_2 S_7 I) = \frac{\lambda (Y + \gamma)}{\beta Y + \lambda} L_7,
\]

\[
\eta_1 S_7 V_7 + \eta_2 S_7 I_7 = \frac{\alpha (Y + \gamma)}{\beta Y + \lambda} I_7 + \frac{\mu_1 (Y + \gamma)}{\beta Y + \lambda} C^I_7, \quad I_7 = \frac{\pi_1}{\sigma_1}, \quad Y_7 = \frac{\pi_2}{\sigma_2}, \quad V_7 = \frac{b I_7}{\varepsilon}.
\]

We obtain

\[
\frac{d\Phi_7}{dt} = \left( 1 - \frac{S_7}{S} \right) \left( \alpha S_7 - \alpha S \right) + \left( \eta_1 S_7 V_7 + \eta_2 S_7 I_7 + \eta_3 S_7 Y_7 \right) \left( 1 - \frac{S_7}{S} \right) - \frac{\lambda (1 - \beta)}{\beta Y + \lambda} \eta_1 S_7 V_7 \frac{S V L_7}{S V_7 L} + \frac{\lambda (1 - \beta)}{\beta Y + \lambda} \eta_2 S_7 I_7 \frac{S L_7}{S^2 L_7} + \frac{\beta (Y + \gamma)}{\beta Y + \lambda} \eta_2 S_7 I_7 \frac{S V L_7}{S V_7 L} - \frac{\beta (Y + \gamma)}{\beta Y + \lambda} \eta_1 S_7 V_7 \frac{S L_7}{S^2 L_7} + \frac{\alpha (Y + \gamma)}{\beta Y + \lambda} \eta_2 S_7 I_7 \frac{S V L_7}{S V_7 L} - \frac{\alpha (Y + \gamma)}{\beta Y + \lambda} \eta_1 S_7 V_7 \frac{S L_7}{S^2 L_7} - \frac{\alpha (Y + \gamma)}{\beta Y + \lambda} \eta_2 S_7 I_7 \frac{S V L_7}{S V_7 L}.
\]
Moreover, we study the e

6. Numerical results and discussions

In this subsection, we choose the following three different initial conditions for system (2.1):

| Table 3. Global stability conditions of the equilibria of model (2.1). |
|-----------------|-----------------|
| Equilibrium point | Global stability conditions |
| $D_0 = (S_0, 0, 0, 0, 0, 0, 0, 0)$ | $\Re_1 \leq 1$ and $\Re_2 \leq 1$ |
| $D_1 = (S_1, I_0, I_1, 0, 0, V_1, 0, 0)$ | $\Re_1 > 1$ and $\Re_1/\Re_2 \leq 1$ |
| $D_2 = (S_2, 0, 0, E_2, Y_2, 0, 0, 0)$ | $\Re_2 > 1$ and $\Re_1/\Re_2 \leq 1$ |
| $D_3 = (S_3, I_2, I_3, 0, 0, V_2, C^I, 0)$ | $\Re_3 > 1$ and $\Re_3 \leq 1$ |
| $D_4 = (S_4, 0, 0, E_4, Y_4, 0, 0, C^I)$ | $\Re_4 > 1$ and $\Re_4 \leq 1$ |
| $D_5 = (S_5, I_5, I_6, 0, E_5, Y_5, V_5, C^I)$ | $\Re_5 > 1$ and $\Re_5 \leq 1$ |
| $D_6 = (S_6, I_6, I_7, 0, E_6, Y_6, V_6, C^I)$ | $\Re_6 > 1$ and $\Re_6 \leq 1$ |
| $D_7 = (S_7, I_7, I_8, E_7, Y_7, V_7, C^I, C^Y)$ | $\Re_7 > 1$ and $\Re_7 \leq 1$ |

6. Numerical results and discussions

In this section, we illustrate the results of Theorems 1–8 by performing numerical simulations. Moreover, we study the effect of HTLV-I infection on the HIV mono-infected individuals by making a comparison between the dynamics of HIV mono-infection and HIV/HTLV-I co-infection. Otherwise, we investigate the influence of HIV infection on the HTLV-I mono-infected individuals by conducting a comparison between the dynamics of HTLV-I mono-infection and HIV/HTLV-I co-infection.

To solve system (2.1) numerically we fix the values of some parameters (see Table 4) and the others will be varied.

6.1. Stability of the equilibria

In this subsection, we choose the following three different initial conditions for system (2.1):
we calculate CTL-mediated immune response is attained. This situation leads to a persistent HTLV mono-infection with unstimulated CTL-mediated immune response.

\[ \eta = \text{G.A.S and this agrees with Theorem 4.} \]

\[ \text{Hence, a chronic HIV mono-infection with HIV-specific} \]

\[ \text{ CTL-mediated immune response.} \]

\[ \text{Choosing selected values of } \eta_1, \eta_2, \eta_3, \sigma_1 \text{ and } \sigma_2 \text{ under the above initial conditions leads to the following scenarios:} \]

\[ \text{Scenario 1 (Stability of } D_0) : \eta_1 = \eta_2 = 0.0001, \eta_3 = 0.001 \text{ and } \sigma_1 = \sigma_2 = 0.2. \]

\[ \text{For this set of parameters, we have } \Re_1 = 0.68 < 1 \text{ and } \Re_2 = 0.23 < 1. \]

\[ \text{Figure 2 displays that the trajectories initiating with Initial-1, Initial-2 and Initial-3 reach the equilibrium } D_0 = (1000, 0, 0, 0, 0, 0, 0). \]

\[ \text{This shows that } D_0 \text{ is G.A.S according to Theorem 1.} \]

\[ \text{In this situation both HIV and HTLV will be died out.} \]

\[ \text{Scenario 2 (Stability of } D_1) : \eta_1 = 0.0005, \eta_2 = 0.0003, \eta_3 = 0.0005, \sigma_1 = 0.003 \text{ and } \sigma_2 = 0.2. \]

\[ \text{With such choice we get } \Re_2 = 0.12 < 1 < 3.02 = \Re_1, \Re_3 = 0.49 < 1 \text{ and hence } \Re_2/\Re_1 = 0.04 < 1. \]

\[ \text{Therefore, the conditions in Table 2 are verified.} \]

\[ \text{In fact, the equilibrium point } D_1 = (331.63, 9.11, 13, 0, 0, 32.51, 0, 0). \]

\[ \text{Figure 3 displays that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to } D_1. \]

\[ \text{Therefore, the numerical results support Theorem 2.} \]

\[ \text{This case corresponds to a chronic HIV mono-infection but with unstimulated CTL-mediated immune response.} \]

\[ \text{Scenario 3 (Stability of } D_2) : \eta_1 = 0.0001, \eta_2 = 0.0002, \eta_3 = 0.01, \sigma_1 = 0.001 \text{ and } \sigma_2 = 0.05. \]

\[ \text{Then, we calculate } \Re_1 = 0.88 < 1 < 2.31 = \Re_2, \Re_4 = 0.77 < 1 \text{ and then } \Re_1/\Re_2 = 0.38 < 1. \]

\[ \text{Hence, the conditions in Table 2 is satisfied.} \]

\[ \text{The numerical results show that } D_2 = (433.33, 0, 0, 87.18, 1.31, 0, 0, 0). \]

\[ \text{Figure 4 illustrates that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to } D_2. \]

\[ \text{Thus, the numerical results consistent with Theorem 3.} \]

\[ \text{This situation leads to a persistent HTLV mono-infection with unstimulated CTL-mediated immune response.} \]

\[ \text{Scenario 4 (Stability of } D_3) : \eta_1 = 0.001, \eta_2 = 0.0001, \eta_3 = 0.005 \text{ and } \sigma_1 = \sigma_2 = 0.1. \]

\[ \text{Then, we calculate } \Re_3 = 1.41 > 1 \text{ and } \Re_5 = 0.32 < 1. \]

\[ \text{Table 2 and Figure 5 show that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to } D_3 = (277.78, 9.85, 10, 0, 0, 2.5, 1.01, 0). \]

\[ \text{Therefore, } D_3 \text{ is G.A.S and this agrees with Theorem 4.} \]

\[ \text{Hence, a chronic HIV mono-infection with HIV-specific CTL-mediated immune response is attained.} \]

\[ \text{Scenario 5 (Stability of } D_4) : \eta_1 = 0.0007, \eta_2 = 0.0001, \eta_3 = 0.1, \sigma_1 = 0.05 \text{ and } \sigma_2 = 0.3. \]

\[ \text{Then, we calculate } \Re_4 = 5.33 > 1 \text{ and } \Re_6 = 0.83 < 1. \]

\[ \text{According to Table 2, } D_4 \text{ exists with } D_4 = (230.77, 0, 0, 118.34, 0.33, 0, 0, 4.33). \]

\[ \text{In Figure 6, we show that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to } D_4 \text{ and then it is G.A.S which agrees with Theorem 5.} \]

\[ \text{Hence, a chronic HTLV mono-infection with HTLV-specific CTL-mediated immune response is attained.} \]

\[ \text{Scenario 6 (Stability of } D_5) : \eta_1 = 0.001, \eta_2 = 0.0001, \eta_3 = 0.01, \sigma_1 = 0.05 \text{ and } \sigma_2 = 0.08. \]

\[ \text{Then, we calculate } \Re_5 = 1.52 > 1, \Re_8 = 0.83 < 1 \text{ and } \Re_1/\Re_2 = 2.19 > 1. \]

\[ \text{Table 2 and the numerical}

| Parameter | Value | Parameter | Value | Parameter | Value |
|-----------|-------|-----------|-------|-----------|-------|
| $\rho$    | 10    | $\delta$  | 0.2   | $\beta$   | 0.7   |
| $\alpha$  | 0.01  | $b$       | 5     | $\gamma$  | 0.02  |
| $\eta_1$  | Varied| $\pi_1$   | 0.1   | $\sigma_1$| Varied|
| $\eta_2$  | Varied| $\pi_2$   | 0.1   | $\sigma_2$| Varied|
| $\eta_3$  | Varied| $\mu_1$   | 0.2   | $\lambda$ | 0.2   |
| $\sigma$  | 0.5   | $\mu_2$   | 0.2   | $\omega$  | 0.01  |
| $\varphi$ | 0.2   | $\epsilon$| 2     | $\psi$    | 0.003 |
results demonstrated in Figure 7 show that $D_5 = (433.33, 3.07, 2.52, 51.0, 0.79, 5.298, 0)$ exists and it is G.A.S and this agrees with Theorem 6. As a result, a chronic co-infection with HIV and HTLV is attained where the HIV-specific CTL-mediated immune response is active and the HTLV-specific CTL-mediated immune response is unstimulated.

**Scenario 7 (Stability of $D_6$):** $\eta_1 = 0.0006, \eta_2 = 0.0001, \eta_3 = 0.04, \sigma_1 = 0.01$ and $\sigma_2 = 0.5$. We compute $\Re_6 = 1.73 > 1, \Re_7 = 0.92 < 1$ and $\Re_2/\Re_1 = 2.97 > 1$. Based on the conditions in Table 2, the equilibrium $D_6 = (321.26, 5.75, 8.2, 39.54, 0.2, 20.51, 0, 1.97)$ exists. Moreover, the numerical results plotted in Figure 8 show that $\Re_6$ is G.A.S and this agrees with Theorem 7. As a result, a chronic co-infection with HIV and HTLV is attained where the HTLV-specific CTL-mediated immune response is active and the HTLV-specific CTL-mediated immune response is unstimulated.

**Scenario 8 (Stability of $D_7$):** $\eta_1 = 0.0006, \eta_2 = 0.0002, \eta_3 = 0.04, \sigma_1 = 0.05$ and $\sigma_2 = 0.5$. These data give $\Re_7 = 1.55 > 1$ and $\Re_8 = 4.31 > 1$. According to Table 2, the equilibrium $D_7$ exists. Figure 9 illustrates that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to $\Re_7$. In this case, a chronic co-infection with HIV and HTLV is attained where both HIV-specific CTL-mediated and HTLV-specific CTL-mediated immune responses are working.

To further confirmation, we calculate the Jacobian matrix $J = J(S, L, I, E, Y, V, C^I, C^Y)$ of system (2.1) as in the following form:

$$J = \begin{pmatrix}
-(\alpha + \eta_1 V + \eta_2 S + \eta_3 Y) & 0 & -\eta_1 S & 0 & -\eta_1 I & 0 & 0 \\
\beta (\eta_1 V + \eta_2 I) & -\gamma & \beta \eta_1 S & (1 - \beta) \eta_1 I & 0 & 0 & 0 \\
\beta \eta_1 V & 0 & 0 & 0 & -\gamma & 0 & 0 \\
0 & \beta \eta_1 S & 0 & 0 & -\eta_1 I & 0 & 0 \\
0 & 0 & 0 & 0 & -\sigma_1 C^I & 0 & 0 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 \\
0 & 0 & 0 & 0 & 0 & 0 & 0
\end{pmatrix}.$$  

Then, we calculate the eigenvalues $\lambda_i, i = 1, 2, ..., 8$ of the matrix $J$ at each equilibrium. The examined steady will be locally stable if all its eigenvalues satisfy the following condition:

$\text{Re}(\lambda_i) < 0, i = 1, 2, ..., 8.$

We use the parameters $\eta_1, \eta_2, \eta_3, \sigma_1$ and $\sigma_2$ the same as given above to compute all positive equilibria and the corresponding eigenvalues. From the scenarios 1–8, we present in Table 5 the positive equilibria, the real parts of the eigenvalues and whether the equilibrium is locally stable or unstable.

### 6.2. Comparison results

In this subsection, we study the influence of HTLV-I infection on HIV mono-infection dynamics, and how affect the HIV infection on the dynamics of HTLV-I mono-infection as well.

### 6.2.1. Impact of HTLV-I infection on HIV mono-infection dynamics

To investigate the effect of HTLV-I infection on HIV mono-infection dynamics, we make a comparison between model (2.1) and the following HIV mono-infection model:

$$\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_1 SV - \eta_2 SI, \\
\dot{L} &= (1 - \beta) (\eta_1 SV + \eta_2 SI) - (\lambda + \gamma) L, \\
\dot{I} &= \beta \eta_1 (\eta_1 SV + \eta_2 SI) + \lambda L - aI - \mu_1 C^I, \\
\dot{Y} &= bI - eV, \\
\dot{V} &= \sigma_1 C^I I - \pi_1 C^I.
\end{align*}$$  

(6.1)
are compatible with the study that has been performed by Vandormael et al. in 2017 [54]. The cells and HIV-specific CTLs are decreased. Although, the concentration of free HIV particles tend to

We fix parameters \( \eta_1 = 0.0006, \eta_2 = 0.0001, \sigma_1 = 0.05, \) and \( \sigma_2 = 0.5 \) and consider the following initial condition:

**Initial-4:** \((S(0), L(0), I(0), E(0), Y(0), V(0), C^I(0), C^V(0)) = (600, 2.4, 18.60, 0.2, 4.5, 1.8, 3.5)\).

We choose two values of the parameter \( \eta_3 \) as \( \eta_3 = 0.04 \) (HIV/HTLV-I co-infection), and \( \eta_3 = 0.0 \) (HIV mono-infection). It can be seen from Figure 10 that when the HIV mono-infected individual is co-infected with HTLV-I then the concentrations of susceptible CD4+T cells, latently HIV-infected cells and HIV-specific CTLs are decreased. Although, the concentration of free HIV particles tend to the same value in both HIV mono-infection and HIV/HTLV-I co-infection. Indeed, such observation are compatible with the study that has been performed by Vandormael et al. in 2017 [54]. The researchers have not found any worthy differences in the concentration of HIV virus particles in comparison between HIV mono-infected and HIV/HTLV-I co-infected patients.

### 6.2.2. Impact of HIV infection on HTLV-I mono-infection dynamics

To investigate the effect of HIV infection on HTLV-I mono-infection dynamics, we make a comparison between model (2.1) and the following HTLV-I mono-infection model:

\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_2 SY, \\
\dot{E} &= \varphi \eta_2 SY - (\psi + \omega) E, \\
\dot{Y} &= \psi E - \delta Y - \mu_2 C^I Y, \\
\dot{C}^I &= \sigma_2 C^I Y - \tau_2 C^I.
\end{align*}
\] (6.2)

We fix parameters \( \eta_3 = 0.01; \sigma_1 = 0.05, \) and \( \sigma_2 = 0.5 \) and consider the following initial condition:

**Initial-5:** \((S(0), L(0), I(0), E(0), Y(0), V(0), C^I(0), C^V(0)) = (700, 4, 2, 21.0198, 5, 4.5, 0.6)\).
We choose two values of the parameters \( \eta_1, \eta_2 \) as \( \eta_1 = 0.001, \eta_2 = 0.0002 \) (HIV/HTLV-I co-infection), and \( \eta_1 = \eta_2 = 0.0 \) (HTLV-I mono-infection). It can be seen from Figure 11 that when the HTLV-I mono-infected individual is co-infected with HIV then the concentrations of susceptible CD4\(^+\)T cells, latently HTLV-infected cells and HTLV-specific CTLs are decreased. Although, the concentration of Tax-expressing HTLV-infected cells tend to the same value in both HTLV-I mono-infection and HIV/HTLV-I co-infection.

6.2.3. Effect of CTL immune response

As we discussed in Section 1 that CTLs have significant important in controlling HIV and HTLV-I mono-infections by killing infected cells. Model (2.1) in the absence of CTL immune response leads to a model with competition between HIV and HTLV-I on CD4\(^+\)T cells:

\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_1 SV - \eta_2 SI - \eta_3 SY, \\
\dot{L} &= (1 - \beta) (\eta_1 SV + \eta_2 SI) - (\lambda + \gamma) L, \\
\dot{I} &= \beta (\eta_1 SV + \eta_2 SI) + \lambda L - aI, \\
\dot{E} &= \varphi \eta_3 SY - (\psi + \omega) E, \\
\dot{Y} &= \psi E - \delta Y, \\
\dot{V} &= bI - \varepsilon V.
\end{align*}
\]

The system has only three equilibria, infection-free equilibrium, \( \bar{D}_0 = (S_0, 0, 0, 0, 0, 0) \), chronic HIV mono-infection equilibrium, \( \bar{D}_1 = (S_1, L_1, I_1, 0, 0, V_1) \) and chronic HTLV mono-infection equilibrium, \( \bar{D}_2 = (S_2, 0, 0, E_2, Y_2, 0) \), where \( S_0, S_1, L_1, I_1, V_1, S_2, E_2 \) and \( Y_2 \) are given in Section 4. The existence of the these three equilibria is determined by two threshold parameters \( \mathcal{R}_1 \) and \( \mathcal{R}_2 \) which are defined in Section 4.

Corollary 1. For system (6.3), the following statements hold true.

(i) If \( \mathcal{R}_1 \leq 1 \) and \( \mathcal{R}_2 \leq 1 \), then \( \bar{D}_0 \) is G.A.S.

(ii) If \( \mathcal{R}_1 > 1 \) and \( \mathcal{R}_2 / \mathcal{R}_1 \leq 1 \), then \( \bar{D}_1 \) is G.A.S.

(iii) If \( \mathcal{R}_2 > 1 \) and \( \mathcal{R}_1 / \mathcal{R}_2 \leq 1 \), then \( \bar{D}_2 \) is G.A.S.

Therefore, the system will tend to one of the three equilibria \( \bar{D}_0, \bar{D}_1 \) and \( \bar{D}_2 \). The above result says that in the absence of immune response, the competition between HIV and HTLV-I consuming common resources, only one type of viruses with maximum basic reproductive ratio can survive. However, in our proposed model (2.1) involving HIV- and HTLV-specific CTLs, HIV and HTLV-I coexist at equilibrium. We can consider this situation as follows. Since CTL immune responses suppress viral progression, the competition between HIV and HTLV-I is also suppressed and the coexistence of HIV and HTLV-I is occurred [55].
Figure 2. The behavior of solution trajectories of system (2.1) when $\mathcal{R}_1 \leq 1$ and $\mathcal{R}_2 \leq 1$. 
Figure 3. The behavior of solution trajectories of system (2.1) when $\mathcal{R}_1 > 1$, $\mathcal{R}_2/\mathcal{R}_1 \leq 1$ and $\mathcal{R}_3 \leq 1$. 

AIMS Mathematics

Volume 6, Issue 2, 1634–1676.
Figure 4. The behavior of solution trajectories of system (2.1) when $\mathcal{R}_2 > 1$, $\mathcal{R}_1/\mathcal{R}_2 \leq 1$ and $\mathcal{R}_4 \leq 1$
Figure 5. The behavior of solution trajectories of system (2.1) when $\mathcal{R}_3 > 1$ and $\mathcal{R}_5 \leq 1$. 
Figure 6. The behavior of solution trajectories of system (2.1) when $\mathcal{R}_4 > 1$ and $\mathcal{R}_6 \leq 1$. 
Figure 7. The behavior of solution trajectories of system (2.1) when $\mathcal{R}_5 > 1$, $\mathcal{R}_8 \leq 1$ and $\mathcal{R}_1/\mathcal{R}_2 > 1$. 
Figure 8. The behavior of solution trajectories of system (2.1) when $\mathcal{R}_6 > 1$, $\mathcal{R}_7 \leq 1$ and $\mathcal{R}_2/\mathcal{R}_1 > 1$. 

(a) Susceptible CD4$^+$T cells
(b) Latently HIV-infected cells
(c) Actively HIV-infected cells
(d) Latently HTLV-infected cells
(e) Tax-expressing HTLV-infected cells
(f) Free HIV particles
(g) HIV-specific CTLs
(h) HTLV-specific CTLs
Figure 9. The behavior of solution trajectories of system (2.1) when $\mathcal{R}_7 > 1$ and $\mathcal{R}_8 > 1$. 
Figure 10. The influence of HTLV-I infection rate ($\eta_3 \neq 0$) on HIV mono-infection dynamics (6.1) will cause a chronic HIV/HTLV-I co-infection.
Figure 11. The influence of HIV infection rates ($\eta_1, \eta_2 \neq 0$) on HTLV mono-infection dynamics (6.2) will cause a chronic HIV/HTLV-I co-infection.
7. Conclusion

This research work formulates a mathematical model which describes the within host dynamics of HIV/HTLV-I co-infection. The model incorporated the effect of HIV-specific CTLs and HTLV-specific CTLs. HIV has two predominant infection modes: the classical VTC infection and CTC spread. The HTLV-I has two ways of transmission, (i) horizontal transmission via direct CTC contact, and (ii) vertical transmission through mitotic division of Tax-expressing HTLV-infected cells. We first proved that the model is well-posed by showing that the solutions are nonnegative and bounded. We derived eight threshold parameters that governed the existence and stability of the eight equilibria of the model. We constructed appropriate Lyapunov functions and applied Lyapunov-LaSalle asymptotic stability theorem to prove the global asymptotic stability of all equilibria. We conducted numerical simulations to support and clarify our theoretical results. We studied the effect of HIV infection on HTLV-I mono-infection dynamics and vice versa. The model analysis suggested that co-infected individuals with both viruses will have smaller number of healthy CD4\(^+\)T cells in comparison with HIV or HTLV-I mono-infected individuals. We discussed the influence of CTL immune response on the co-infection dynamics.

Our model can be extended in many directions:

- In our model (2.1), we assumed that susceptible CD4\(^+\)T cells are produced at a constant rate \(\rho\) and have a linear death rate \(\alpha S\). It would be more reasonable to consider the density dependent production rate. One possibility is to assume a logistic growth for the susceptible CD4\(^+\)T cells in the absence of infection. Moreover, the model assumed bilinear incidence rate of infections, \(\eta_1SV, \eta_2SI\) and \(\eta_3SY\). However, such bilinear form may not describe the virus dynamics during the full course of infection. Therefore, it is reasonable to consider other forms of the incidence rate such as: saturated incidence, Beddington-DeAngelis incidence and general incidence [56–58].
- Model (2.1) assumed that once susceptible CD4\(^+\)T cell is contacted by an HIV or HIV-infected or HTLV-infected cell it becomes latently or actively infected instantaneously. However, such process needs time. Intracellular time delay has a significant effect on the virus dynamics. Delayed viral infection models have been constructed and analyzed in several works (see, e.g., [59–64]).
- Model (2.1) assumes that cells and viruses are equally distributed in the domain with no spatial variations. Taking into account spatial variations in the case of HIV/HTLV-I co-infection will be significant [65,66].

We leave these extensions as a future project.

Acknowledgment

This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia under grant no. (KEP-PhD-20-130-41). The authors, therefore, acknowledge with thanks DSR technical and financial support.

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.
References

1. WHO, *Global Health Observatory (GHO) data. HIV/AIDS*, 2018. Available from: http://www.who.int/gho/hiv/en/.

2. M. A. Nowak, R. M. May, *Virus dynamics: Mathematical principles of immunology and virology*, Oxford University Press, 2001.

3. M. A. Nowak, C. R. M. Bangham, Population dynamics of immune responses to persistent viruses, *Science, 272* (1996), 74–79.

4. K. D. Pedro, A. J. Henderson, L. M. Agosto, Mechanisms of HIV-1 cell-to-cell transmission and the establishment of the latent reservoir, *Virus Res.*, 265 (2019), 115–121.

5. L. Rong, A. S. Perelson, Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy, *PLoS Comput. Biol.*, 5 (2009), 1–18.

6. D. S. Callaway, A. S. Perelson, HIV-1 infection and low steady state viral loads, *Bull. Math. Biol.*, 64 (2002), 29–64.

7. A. M. Elaiw, S. A. Azoz, Global properties of a class of HIV infection models with Beddington-DeAngelis functional response, *Math. Method. Appl. Sci.*, 36 (2013), 383–394.

8. A. M. Elaiw, M. A. Alshaikh, Stability of discrete-time HIV dynamics models with three categories of infected CD4+ T-cells, *Adv. Differ. Equ.*, 2019 (2019), 1–24.

9. A. M. Elaiw, N. H. AlShamrani, Stability of a general CTL-mediated immunity HIV infection model with silent infected cell-to-cell spread, *Adv. Differ. Equ.*, 2020 (2020), 1–25.

10. A. M. Elaiw, E. K. Elnahary, A. A. Raezah, Effect of cellular reservoirs and delays on the global dynamics of HIV, *Adv. Differ. Equ.*, 2018 (2018), 1–36.

11. B. Buonomo, C. Vargas-De-Leon, Global stability for an HIV-1 infection model including an eclipse stage of infected cells, *J. Math. Anal. Appl.*, 385 (2012), 709–720.

12. H. Liu, J. F. Zhang, Dynamics of two time delays differential equation model to HIV latent infection, *Physica A*, 514 (2019), 384–395.

13. S. Iwami, J. S. Takeuchi, S. Nakaoka, F. Mammano, F. Clavel, H. Inaba, et al. Cell-to-cell infection by HIV contributes over half of virus infection, *eLife*, 4 (2015), 1–16.

14. M. Sourisseau, N. Sol-Foulon, F. Porrot, F. Blanchet, O. Schwartz, Inefficient human immunodeficiency virus replication in mobile lymphocytes, *J. Virol.*, 81 (2007), 1000–1012.

15. A. Sigal, J. T. Kim, A. B. Balazs, E. Dekel, A. Mayo, R. Milo, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy, *Nature*, 477 (2011), 95–98.

16. Y. Gao, J. Wang, Threshold dynamics of a delayed nonlocal reaction-diffusion HIV infection model with both cell-free and cell-to-cell transmissions, *J. Math. Anal. Appl.*, 488 (2020), 124047.

17. A. Mojaver, H. Kheiri, Mathematical analysis of a class of HIV infection models of CD4+T-cells with combined antiretroviral therapy, *Appl. Math. Comput.*, 259 (2015), 258–270.
18. X. Wang, S. Tang, X. Song, L. Rong, Mathematical analysis of an HIV latent infection model including both virus-to-cell infection and cell-to-cell transmission, *J. Biol. Dynam.*, **11** (2017), 455–483.

19. H. R. Norrgren, S. Bamba, O. Larsen, Z. Da Silva, P. Aaby, T. Koivula, et al. Increased prevalence of HTLV-1 in patients with pulmonary tuberculosis coinfected with HIV, but not in HIV-negative patients with tuberculosis, *J. Acq. Immn. Def.*, **48** (2008), 607–610.

20. A. G. Lim, P. K. Maini, HTLV-Infection: A dynamic struggle between viral persistence and host immunity, *J. Theor. Biol.*, **352** (2014), 92–108.

21. X. Pan, Y. Chen, H. Shu, Rich dynamics in a delayed HTLV-I infection model: Stability switch, multiple stable cycles, and torus, *J. Math. Anal. Appl.*, **479** (2019), 2214–2235.

22. M. Y. Li, A. G. Lim, Modelling the role of Tax expression in HTLV-1 persistenve in vivo, *Bull. Math. Biol.*, **73** (2011), 3008–3029.

23. B. Asquith, C. R. M. Bangham, The dynamics of T-cell fraticide: application of a robust approach to mathematical modeling in immunology, *J. Theor. Biol.*, **222** (2003), 53–69.

24. S. Tokudome et al., Incidence of adult T cell leukemia/lymphoma among human T lymphotropic virus type 1 carriers in Saga, Japan, *Cancer Res.*, **49** (1989), 226–228.

25. N. I. Stilianakis, J. Seydel, Modeling the T-cell dynamics and pathogenesis of HTLV-I infection, *Bull. Math. Biol.*, **61** (1999), 935–947.

26. H. Gomez-Acevedo, M. Y. Li, Backward bifurcation in a model for HTLV-I infection of CD4+ T cells, *Bull. Math. Biol.*, **67** (2005), 101–114.

27. C. Vargas-De-Leon, The complete classification for global dynamics of a model for the persistence of HTLV-1 infection, *Appl. Math. Comput.*, **237** (2014), 489–493.

28. X. Song, Y. Li, Global stability and periodic solution of a model for HTLV-1 infection and ATL progression, *Appl. Math. Comput.*, **180** (2006), 401–410.

29. E. S. Rosenberg, M. Altfeld, S. H. Poon, M. N. Phillips, B. M. Wilkes, R. L. Eldridge, et al., Immune control of HIV-1 following early treatment of acute infection, *Nature*, **407** (2000), 523–526.

30. A. M. Elaiw, N. H. AlShamrani, Global stability of a delayed adaptive immunity viral infection with two routes of infection and multi-stages of infected cells, *Commun. Nonlinear Sci.*, **86** (2020), 105259.

31. B. Asquith, C. R. M. Bangham, Quantifying HTLV-I dynamics, *Immunol. Cell Biol.*, **85** (2007), 280–286.

32. C. Bartholdy, J. P. Christensen, D. Wodarz, A. R. Thomsen, Persistent virus infection despite chronic cytotoxic T-lymphocyte activation in gamma interferon-deficient mice infected with lymphocytic choriomeningitis virus, *J. Virol.*, **74** (2000), 10304–10311.

33. H. Gomez-Acevedo, M. Y. Li, S. Jacobson, Multi-stability in a model for CTL response to HTLV-I infection and its consequences *Bull. Math. Biol.*, **72** (2010), 681–696.

34. M. Y. Li, H. Shu, Multiple stable periodic oscillations in a mathematical model of CTL response to HTLV-I infection, *Bull. Math. Biol.*, **73** (2011), 1774–1793.
35. L. Wang, Z. Liu, Y. Li, D. Xu, Complete dynamical analysis for a nonlinear HTLV-I infection model with distributed delay, CTL response and immune impairment, *Discrete Cont. Dyn. B.*, 25 (2020), 917–933.

36. Y. Wang, J. Liu, J. M. Heffernan, Viral dynamics of an HTLV-I infection model with intracellular delay and CTL immune response delay, *J. Math. Anal. Appl.*, 459 (2018), 506–527.

37. F. Li, W. Ma, Dynamics analysis of an HTLV-I infection model with mitotic division of actively infected cells and delayed CTL immune response, *Math. Method. Appl. Sci.*, 41 (2018), 3000–3017.

38. S. Li, Y. Zhou, Backward bifurcation of an HTLV-I model with immune response, *Discrete Cont. Dyn. B.*, 21 (2016), 863–881.

39. C. Casoli, E. Pilotti, U. Bertazzoni, Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression, *AIDS Rev.*, 9 (2007), 140–149.

40. E. Pilotti, M. V. Bianchi, A. De Maria, F. Bozzano, M. G. Romanelli, U. Bertazzoni, et al. HTLV-1/-2 and HIV-1 co-infections: retroviral interference on host immune status, *Front. Microbiol.*, 4 (2013), 1–13.

41. M. A. Beilke, K. P. Theall, M. O’Brien, J. L. Clayton, S. M. Benjamin, E. L. Winsor, et al. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2, *Clin. Infect. Dis.*, 39 (2004), 256–263.

42. C. Isache, M. Sands, N. Guzman, D. Figueroa, HTLV-1 and HIV-1 co-infection: A case report and review of the literature, *IDCases*, 4 (2016), 53–55.

43. M. Tulius Silva, O. de Melo Espíndola, A. C. Bezerra Leite, A. Araújo, Neurological aspects of HIV/human T lymphotropic virus coinfection, *AIDS Rev.*, 11 (2009), 71–78.

44. N. Rockwood, L. Cook, H. Kagdi, S. Basnayake, C. R. M. Bangham, A. L. Pozniak, et al. Immune compromise in HIV-1/HTLV-1 co-infection with paradoxical resolution of CD4 lymphocytosis during antiretroviral therapy: A case report, *Medicine*, 94 (2015), 1–4.

45. C. Brites, J. Sampalo, A. Oliveira, HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression, *AIDS Rev.*, 11 (2009), 8–16.

46. V. E. V. Geddes, D. P. José, F. E. Leal, D. F. Nixond, A. Tanuri, R. S. Aguiar, HTLV-1 Tax activates HIV-1 transcription in latency models, *Virology*, 504 (2017), 45–51.

47. R. Bingham, E. Dykeman, R. Twarock, RNA virus evolution via a quasispecies-based model reveals a drug target with a high barrier to resistance, *Viruses*, 9 (2017), 347.

48. E. Ticona, M. A. Huaman, O. Yanque, J. R. Zunt, HIV and HTLV-1 coinfection: the need to initiate antiretroviral therapy, *J. Int. Assoc. Provid. AIDS Care*, 12 (2013), 373–374.

49. N. Bellomo, R. Bingham, M. A. J. Chaplain, G. Dosi, G. Forni, D. A. Knopoff, et al. A multi-scale model of virus pandemic: Heterogeneous interactive entities in a globally connected world, *Math. Mod. Meth. Appl. S.*, 30 (2000), 1591–1651.

50. A. Korobeinikov, Global properties of basic virus dynamics models, *Bull. Math. Biol.*, 66 (2004), 879–883.

51. E. A. Barbashin, *Introduction to the theory of stability*, Wolters-Noordhoff, 1970.

52. J. P. LaSalle, *The stability of dynamical systems*, Philadelphia, SIAM, 1976.
53. A. M. Lyapunov, The general problem of the stability of motion, *Int. J. Control*, **55** (1992), 531–534.

54. A. Vandormael, F. Rego, S. Danaviah, L. Carlos Junior Alcantara, D. R. Boulware, T. de Oliveira, CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-1/HIV co-infected patients, *Curr. HIV Res.*, **15** (2017), 225–231.

55. T. Inoue, T. Kajiwara, T. Sasaki, Global stability of models of humoral immunity against multiple viral strains, *J. Biol. Dynam.*, **4** (2010), 282–295.

56. G. Huang, Y. Takeuchi, W. Ma, Lyapunov functionals for delay differential equations model of viral infections, *SIAM J. Appl. Math.*, **70** (2010), 2693–2708.

57. A. M. Elaiw, I. A. Hassanien, S. A. Azoz, Global stability of HIV infection models with intracellular delays, *J. Korean Math. Soc.*, **49** (2012), 779–794.

58. A. M. Elaiw, S. F. Alshehaiween, Global stability of delay-distributed viral infection model with two modes of viral transmission and B-cell impairment, *Math. Method. Appl. Sci.*, **43** (2020), 6677–6701.

59. P. W. Nelson, J. D. Murray, A. S. Perelson, A model of HIV-1 pathogenesis that includes an intracellular delay, *Math. Biosci.*, **163** (2000), 201–215.

60. A. M. Elaiw, A. A. Raezah, Stability of general virus dynamics models with both cellular and viral infections and delays, *Math. Method. Appl. Sci.*, **40** (2017), 5863–5880.

61. A. M. Elaiw, N. A. Almulallem, Global dynamics of delay-distributed HIV infection models with differential drug efficacy in cocirculating target cells, *Math. Method. Appl. Sci.*, **39** (2016), 4–31.

62. A. M. Elaiw, S. F. Alshehaiween, A. D. Hobiny, Global properties of a delay-distributed HIV dynamics model including impairment of B-cell functions, *Mathematics*, **7** (2019), 1–27.

63. A. M. Elaiw, E. K. Elnahary, Analysis of general humoral immunity HIV dynamics model with HAART and distributed delays, *Mathematics*, **7** (2019), 1–35.

64. R. V. Culshaw, S. Ruan, G. Webb, A mathematical model of cell-to-cell spread of HIV-1 that includes a time delay, *J. Math. Biol.*, **46** (2003), 425–444.

65. N. Bellomo, K. J. Painter, Y. Tao, M. Winkler, Occurrence vs. Absence of taxis-driven instabilities in a May-Nowak model for virus infection, *SIAM J. Appl. Math.*, **79** (2019), 1990–2010.

66. A. M. Elaiw, A. D. AlAgha, Global analysis of a reaction-diffusion within-host malaria infection model with adaptive immune response, *Mathematics*, **8** (2020), 1–32.